

RESEARCH ARTICLE

Molecular determinants of α V β 5 localization in flat clathrin lattices – role of α V β 5 in cell adhesion and proliferation

Alba Zuidema^{1,*}, Wei Wang^{1,*}, Maaike Kreft¹, Onno B. Bleijerveld², Liesbeth Hoekman², Jonas Aretz³, Ralph T. Böttcher³, Reinhard Fässler³ and Arnoud Sonnenberg^{1,‡}

ABSTRACT

The vitronectin receptor integrin α V β 5 can reside in two distinct adhesion structures – focal adhesions (FAs) and flat clathrin lattices (FCLs). Here, we investigate the mechanism that regulates the subcellular distribution of β 5 in keratinocytes and show that β 5 has approximately 7- and 5-fold higher affinity for the clathrin adaptors ARH (also known as LDLRAP1) and Numb, respectively, than for the talin 1 (TLN1); all proteins that bind to the membrane-proximal NPxY motif of the β 5 cytoplasmic domain. Using mass spectrometry, we identified β 5 interactors, including the Rho GEFs p115Rho-GEF and GEF-H1 (also known as ARHGEF1 and ARHGEF2, respectively), and the serine protein kinase MARK2, depletion of which diminishes the clustering of β 5 in FCLs. Replacement of two serine residues (S759 and S762) in the β 5 cytoplasmic domain with phospho-mimetic glutamate residues causes a shift in the localization of β 5 from FAs into FCLs without affecting the interactions with MARK2, p115Rho-GEF or GEF-H1. Instead, we demonstrate that changes in the actomyosin-based cellular contractility by ectopic expression of activated Rho or disruption of microtubules regulates β 5 localization. Finally, we present evidence that β 5 in either FAs or FCLs functions to promote adhesion to vitronectin, cell spreading, and proliferation.

KEY WORDS: Flat clathrin lattice, Focal adhesion, Integrin, Vitronectin, Proliferation

INTRODUCTION

Cell adhesion to neighboring cells and/or the surrounding extracellular matrix (ECM) is essential in multicellular organisms for tissue development and homeostasis. Integrins are a major family of transmembrane cell–ECM adhesion receptors that are formed through heterodimerization of an α and a β subunit, and link the intracellular cytoskeleton to ECM components, such as collagens, laminins, fibronectin and vitronectin (Hynes, 2002). The integrin α V β 5 binds to the arginine (R), glycine (G), aspartic

acid (D) tri-peptide in vitronectin. This integrin is dispensable for normal mouse development (Huang et al., 2000) but is required for photoreceptor function and viability by regulating retinal adhesion (Nandrot et al., 2006). Additionally, increased vitronectin synthesis and elevated levels of integrin β 5 correlate with disease progression of different types of cancer, including colorectal, brain, breast and non-small cell lung cancer (Gladson et al., 1997; Uhm et al., 1999; Bianchi-Smiraglia et al., 2013; Bai et al., 2015; Vogetseder et al., 2013; Schittenhelm et al., 2013; Tomasini-Johansson et al., 1994). It has been shown that integrin β 5 plays a role *in vivo* in adhesion and early invasion of metastatic colon carcinoma cells into the liver (Enns et al., 2005) and in tumor growth of breast carcinoma cells (Bianchi-Smiraglia et al., 2013).

Intriguingly, integrin β 5 can be found in two distinct adhesion complexes – focal adhesions (FAs) and flat clathrin lattices (FCLs) (Lock et al., 2019; Zuidema et al., 2020; Baschieri et al., 2020). FAs serve as anchorage sites between the ECM and the intracellular actin cytoskeleton and regulate multiple and wide-ranging cellular processes by functioning as bidirectional signaling units (Burridge, 2017). In contrast, the assembly of adhesion complexes containing integrin β 5 outside of FAs (Wayner et al., 1991) has recently received more attention, as multiple studies have reported on β 5-containing FCLs, clathrin plaques or reticular adhesions (Zuidema et al., 2018; Leyton-Puig et al., 2017; Lock et al., 2018; Baschieri et al., 2018), which all refer to the same type of structure (Lock et al., 2019). Integrin β 5-containing FCLs are structurally and dynamically different from the canonical clathrin pits (Baschieri et al., 2020; Grove et al., 2014; Lampe et al., 2016) and FAs (Lock et al., 2019; Zuidema et al., 2020). They have been proposed to form as a consequence of frustrated clathrin-mediated endocytosis and might mediate cell–ECM adhesion during mitosis (Lock et al., 2018), serve as platforms for cytoskeletal anchorage in skeletal muscle (Franck et al., 2019), and promote growth factor receptor signaling (Leyton-Puig et al., 2017; Baschieri et al., 2018). The assembly of integrin β 5 in FCLs is characteristic for a wide range of cell types and a single cell can contain both β 5-containing FCLs and FAs (Lock et al., 2018).

Previously, our laboratory investigated the mechanisms controlling the assembly of β 5-containing FCLs in keratinocytes and demonstrated that binding of the cytoplasmic domain of β 5 by the clathrin adaptor proteins ARH (also known as LDLRAP1), Numb, EPS15 and EPS15L1 is required for FCL formation (Zuidema et al., 2018). However, how the subcellular localization of integrin β 5 in FAs versus FCLs contributes towards its function is still unclear. In this study, we further analyzed the molecular mechanisms that control the assembly of β 5-containing adhesion complexes in more detail and demonstrate that the integrin β 5 cytoplasmic domain binds more strongly to ARH and Numb than to talin 1 (hereafter talin), and displays only very low binding to kindlin-1 or -2 (kindlin-1/2; also known as FERMT1 and

¹Division of Cell Biology I, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands. ²Proteomics Facility, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands. ³Department of Molecular Medicine, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany.

*These authors contributed equally to this work

‡Author for correspondence (a.sonnenberg@nki.nl).

© A.Z., 0000-0002-9990-5728; W.W., 0000-0003-4869-6716; M.K., 0000-0003-1301-2898; O.B.B., 0000-0002-9395-2347; L.H., 0000-0002-3552-6390; J.A., 0000-0002-4623-5820; A.S., 0000-0001-9585-468X

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

Handling Editor: Michael Way

Received 13 October 2021; Accepted 20 April 2022

FERMT2). Furthermore, phospho-mimetic mutation of two serine residues (S759/762) in a $\beta 5$ -SERS motif, which has been implicated in controlling cell attachment and migration (Li et al., 2010), promotes localization in FCLs. We also report that destabilization of microtubules promotes relocation of integrin $\beta 5$ from FCLs into FAs through modulation of tension. Finally, we present evidence that $\beta 5$ mediates adhesion and promotes cell proliferation regardless of its localization in FAs or FCLs.

RESULTS

Localization of integrin $\beta 5$ in human cancer cells

The level of integrin $\beta 5$, which can reside in two distinct adhesions in a variety of cell lines (Table S1), has been correlated with disease progression of colorectal, brain, breast and non-small cell lung cancer (Gladson et al., 1997; Uhm et al., 1999; Bianchi-Smiraglia et al., 2013; Bai et al., 2015; Vogetseder et al., 2013; Schittenhelm et al., 2013; Tomasini-Johansson et al., 1994). Because the subcellular localization of proteins plays an important role in the regulation of cell function, we investigated the localization of $\beta 5$ in a panel of human cancer cell lines derived from colorectal (HT29, SW480, and SW620), brain (U251MG), breast (MCF7 and MDA-MB-231) and lung (A549) cancers (Fig. 1; Fig. S1). Similar to PA-JEB/ $\beta 4$ and HaCaT keratinocytes (Zuidema et al., 2018), $\beta 5$ localizes almost exclusively in FCLs in SW620 cells. In MCF7 cells, $\beta 5$ can be found in both FAs and FCLs, but localization in FCLs is favored. MDA-MB-231 cells hardly form $\beta 5$ -containing FCLs. Integrin $\beta 5$ can be found predominantly in FAs in HT29, U251MG and A549 cells. In SW480 cells, $\beta 5$ is distributed roughly equally between FAs and FCLs (Fig. 1; Fig. S1). Based on these observations, we conclude that the localization of $\beta 5$ is independent of tissue origin.

Selective binding of ARH by integrin $\beta 5$

To understand the mechanism by which integrin $\beta 5$ uniquely localizes in two types of adhesion complexes, we compared the sequence of and adaptor proteins associated with integrin $\beta 5$ versus $\beta 1$ and $\beta 3$. All three integrin subunits contain a highly conserved membrane proximal (MP) NPxY motif that serves as a canonical binding site for the talin phospho-tyrosine-binding (PTB)/4.1 protein, ezrin, radixin and moesin (FERM) domain (from now on referred to as the talin head domain; THD) and the PTB domain-containing clathrin adaptor proteins ARH, Numb and Dab2 (Calderwood et al., 2003; Zuidema et al., 2018). We hypothesized that differential binding between the integrin $\beta 1$, $\beta 3$ and $\beta 5$ cytoplasmic domains and the PTB-containing adaptor proteins could contribute to the distinct subcellular distribution pattern of these integrins. To test this, we generated integrin chimeras fused to a promiscuous biotin ligase (BirA*) to perform proximity biotinylation (BioID) experiments with PA-JEB/ $\beta 4$ keratinocytes grown for 1 day in DMEM with fetal calf serum (FCS) (Roux et al., 2012). Similar to the integrin $\beta 5^{\text{ex}}/\beta 1^{\text{in}}$ and $\beta 5^{\text{ex}}/\beta 3^{\text{in}}$ (ex, extracellular; in, intracellular) chimeras previously described (Zuidema et al., 2018), the integrin $\beta 5^{\text{ex}}/\beta 1^{\text{in}}$ - and $\beta 5^{\text{ex}}/\beta 3^{\text{in}}$ -BirA* fusion proteins preferentially localize in FAs (Fig. 2A). BioID experiments with subsequent western blot analysis showed strong biotinylation of the clathrin adaptor proteins ARH and Numb by $\beta 5$ -BirA*, but not by the $\beta 5^{\text{ex}}/\beta 1^{\text{in}}$ - and $\beta 5^{\text{ex}}/\beta 3^{\text{in}}$ -BirA* fusion proteins. Furthermore, the $\beta 5$ -BirA* construct was unable to biotinylate talin, in stark contrast to the $\beta 5^{\text{ex}}/\beta 1^{\text{in}}$ -BirA* chimera (Fig. 2B). We further validated these findings by performing pulldown experiments with integrin $\beta 1$, $\beta 3$ and $\beta 5$ cytoplasmic domain peptides. Again, we detected an interaction between $\beta 5$ and

ARH and Numb and between $\beta 1$ and the FA proteins talin, KANK-2 and kindlin-1/2 (Fig. 2C). Microscale thermophoresis (MST) measurements confirmed the binding of $\beta 5$ to ARH and showed that the affinity of the cytoplasmic tail peptide of $\beta 5$ for ARH ($K_d=5.6\pm 1.4\ \mu\text{M}$; mean \pm s.d.) is higher than that for Numb ($K_d=28.5\pm 7.7\ \mu\text{M}$) and the talin-1 head domain (THD1) ($K_d=41.7\pm 9.5\ \mu\text{M}$), whereas no binding of $\beta 1$ and $\beta 3$ to ARH and Numb was detected in the concentration range tested (up to 50 μM for $\beta 1$ and 75 μM for $\beta 3$; Fig. 2D). Together, these experiments demonstrate that the cytoplasmic domain of integrin $\beta 5$ confers a unique ability to bind to the clathrin adaptor proteins ARH and Numb, despite the presence of the highly conserved MP-NPxY and MD-NxxY motifs present in the cytoplasmic domains of both integrin $\beta 1$ and $\beta 3$.

Integrin $\beta 5$ differs from $\beta 1$ and $\beta 3$ by the presence of an 8-amino-acid insertion between the MP-NPxY and MD-NxxY motifs, which might be responsible for the differential binding between the integrin $\beta 1$, $\beta 3$ and $\beta 5$ cytoplasmic tails with the clathrin adaptors. However, deletion of the $\beta 5$ 8-amino-acid sequence prevented neither the clustering of $\beta 5$ in FCLs (Zuidema et al., 2018) nor the binding of cytoskeletal or clathrin adaptor proteins to the $\beta 5$ tail (Fig. 2C). On the other hand, the binding of $\beta 5$ to SNX17 was abrogated by the deletion (Fig. 2C).

Interestingly, in contrast to integrin $\beta 1$ and $\beta 3$, we detected no interaction between $\beta 5$ and kindlin-1/2 in our peptide pulldown experiments (Fig. 2C) and only a low affinity interaction by MST (Fig. S2A). THD1 bound with a slightly higher affinity to the integrin $\beta 5$ subunit compared to $\beta 1$ and $\beta 3$ *in vitro* (Fig. S2A), which is in agreement with reported affinities of talin for $\beta 1$ and $\beta 3$ (Anthis et al., 2010). Similar to talin, kindlin-1/2 can also connect integrins to the actin cytoskeleton. We hypothesized that the reduced binding of kindlin-1/2 to $\beta 5$ as compared to that seen with $\beta 1$ and $\beta 3$ could contribute to its localization in FCLs versus FAs. To test this, we introduced a disruptive Y>A mutation in the MD-NxxY motif responsible for kindlin-1/2 binding in the $\beta 5^{\text{ex}}/\beta 3^{\text{in}}$ chimera. This construct (Itg. $\beta 5/\beta 3^{\text{Y786A}}$) localized predominantly in FAs, similar to the wild-type $\beta 5^{\text{ex}}/\beta 3^{\text{in}}$ chimera (Fig. S2B), indicating that the absence of kindlin-1/2 binding does not influence integrin $\beta 5$ localization.

The integrin $\beta 1$, $\beta 3$ and $\beta 5$ subunits also differ in charged residues adjacent to the membrane-proximal NPxY motif. Changing the charged into noncharged residues, and vice versa, at the -5 and $+2$ position relative to the tyrosine residue of the $\beta 3$ NPxY motif has been shown to inhibit PTB domain binding (Calderwood et al., 2003). Integrin $\beta 5$ contains a positively charged residue at position $+2$ relative to the tyrosine of its NPxY motif, in contrast to an uncharged or a negatively charged residue for $\beta 1$ and $\beta 3$, respectively (Fig. S3A). Another striking difference between the amino acid sequences of the integrin tails is the tyrosine at position -8 in $\beta 5$ versus the tryptophan present at the corresponding position in $\beta 1$ and $\beta 3$ (Fig. S3A). We wondered whether these residues could play a role in determining the subcellular distribution of $\beta 5$, potentially through regulating the binding affinity of ARH. To this end, we introduced $\beta 5$ mutants containing Y766W, both K776E and P777A, or a 12-amino-acid substitution of residues 766–777 to mimic the sequence of integrin $\beta 3$ in $\beta 5$ -deficient keratinocytes. However, none of these $\beta 5$ mutants displayed an altered localization compared to the wild-type integrin (Fig. S3A,B).

Serine residues 759 and 762 regulate integrin $\beta 5$ localization

The amino acid sequence Ser-Glu-Arg-Ser (SERS) is another region of the $\beta 5$ cytoplasmic domain that we hypothesized could influence its localization. The serine residues in this stretch of amino




Fig. 1. Subcellular distribution of integrin $\beta 5$ in keratinocytes and multiple cancer cells. (A,B) Immunofluorescence images showing integrin $\beta 5$ (Itg. $\beta 5$; green in merge), vinculin (A) or clathrin (B) (red in merge), actin (blue), DAPI (cyan). Scale bars: 20 μ m. (C,D) Quantifications of integrin $\beta 5$ colocalization with vinculin in FAs (C) or with clathrin in FCLs (D). Data were obtained from three independent experiments. Total cells analyzed per condition: HT29=86 (C) and 94 (D), SW480=89 (C) and 115 (D), SW620=70 (C) and 90 (D), MCF7=82 (C) and 88 (D), MDA-MB-231=79 (C) and 89 (D), U251MG=97 (C) and 88 (D), A549=55 (C) and 63 (D). Representative images of U251MG and A549 cells are shown in Fig. S1. Box plots range from the 25th to 75th percentile; central line indicates the median; whiskers show smallest to largest value.



4

Fig. 2. Adaptor protein binding to integrin β subunits. (A) Colocalization of integrin chimeras fused to the promiscuous biotin ligase BirA* (green in merge) with vinculin (red; left panels) or clathrin (red; right panels) in PA-JEB/ β 4 keratinocytes. Actin is shown in blue. Nuclei are stained with DAPI (cyan). Scale bars: 20 μ m. (B) Representative western blots of BiolD assays performed using the integrin chimeras shown in A. Quantifications of ARH, Numb and talin signal intensities normalized to streptavidin-HRP levels are shown ($n=3$; bars show mean \pm s.d.). (C) Representative western blots of pulldown assays (from two repeats) using synthetic integrin β cytoplasmic domains in RAC-11P cell lysates. (D) MST assay demonstrating binding of ARH, Numb, and talin-1 head domain (THD1) peptides to the β 5 cytoplasmic domain ($n\geq 5$). Inset in top panel shows calculated K_d (mean \pm s.d.). β 5-CT, β 5 cytoplasmic tail; β 5 Δ 8 aa, β 5 mutant carrying a deletion of a stretch of 8 amino acids (Val⁷⁸³–Phe⁷⁹⁰) located between the NPxY and NxxY motifs in the cytoplasmic domain of β 5; Itg. β 5/ β 1, chimeric receptor containing the extracellular and transmembrane domain of β 5 and the cytoplasmic domain of β 1; Itg. β 5/ β 3, chimeric receptor containing the extracellular and transmembrane domain of β 5 and the cytoplasmic domain of β 3; scr, scrambled; WCL, whole-cell lysates.

acids are phosphorylated by p21-activated kinase 4 (PAK4) (Li et al., 2010; Zhang et al., 2002) and PAK4 binding to the phosphorylated residues accelerated integrin β 5 turnover within lamellipodial structures (Li et al., 2010; Zhang et al., 2002). To investigate whether the β 5-SERS could play a role in regulating the localization of β 5, we generated β 5-deficient keratinocytes expressing a β 5-SERS phospho-mimetic (S759E/S762E; hereafter S759/762E) or phospho-inhibitory (S759A/S762A; hereafter S759/762A) mutant (Fig. 3A). We observed reduced localization of the phospho-mimetic integrin β 5-S759/762E mutant in FAs and increased localization in FCLs, as indicated by reduced colocalization with vinculin and increased colocalization with clathrin. No significant difference in localization to either FAs or FCLs was observed with the β 5-S759/762A mutants (Fig. 3B–E). To further validate whether phosphorylation of the SERS region regulates β 5 localization, we treated PA-JEB/ β 4 keratinocytes with calyculin A, a potent inhibitor of phosphatase-1 and -2A. Similar to the β 5-S759/762E-expressing cells, treatment with calyculin A decreased the localization of integrin β 5 in FAs of PA-JEB/ β 4 keratinocytes (Fig. 3F–I). We repeated this experiment with PA-JEB keratinocytes, which lack β 4 and in which β 5 is found at higher abundance in FAs than in PA-JEB/ β 4 cells (Wang et al., 2020). In line with our previous findings, calyculin A treatment reduced the localization of integrin β 5 in FAs and increased the localization in FCLs (Fig. 3J,K; Fig. S3C,D).

To identify a kinase that perhaps could be responsible for the β 5-S759/762 phosphorylation, we used a matched set of rabbit serum containing antibodies against β 5 (5HK2) or β 6 (5HK1; negative control) to immunoprecipitate these integrin subunits and analyzed the interacting proteins by mass spectrometry (Fig. 4A,B; Tables S2 and S3). In contrast to previous studies (Li et al., 2010; Zhang et al., 2002), PAK4 was not found as a significant interactor of integrin β 5. The microtubule affinity-regulating kinase 2 (MARK2; also known as Par1b) was the only serine/threonine-protein kinase identified as a significant interactor of β 5 in both PA-JEB/ β 4 and HaCaT keratinocytes (Fig. 4A,B). In addition, p115-RhoGEF (also known as ARHGEF1) and GEF-H1 (also known as ARHGEF2) and multiple proteins that associate with the microtubule network were identified as β 5 interactors, including kinesin-1 heavy (KIF5B) and light chain (KLC1) (Kaneko et al., 2020; Jiang et al., 2019), EB1 (also known as MAPRE1) (Askham et al., 2002), HOOK2 (Walenta et al., 2001; Krämer and Phistry, 1996) and NUDC (Aumais et al., 2003, 2001) (Fig. 4A,B; Tables S2 and S3). The MARK2-interacting protein microtubule crosslinking factor 1 (MTCL1) (Sato et al., 2013) was found as a significant interactor of β 5, but

only in PA-JEB/ β 4 cells (Fig. 4A). The interactions between β 5 and MARK2, p115-RhoGEF and GEF-H1 were validated by co-immunoprecipitation and western blot analysis (Fig. 4C). To assess whether MARK2 could play a role in regulating the subcellular distribution of β 5, we depleted MARK2 in PA-JEB/ β 4 cells using siRNAs and determined the localization of β 5 in FAs and FCLs (Fig. 4D–H). MARK2 depletion resulted in a significant increase of β 5 clustering within FAs with a concomitant decrease within FCLs (Fig. 4D–H). The same effect was also observed in β 5-deficient PA-JEB/ β 4 cells expressing the wild-type β 5 subunit but not for the β 5-S759/762E mutant (Fig. 4I), suggesting that MARK2 could promote the localization of β 5 in FCLs through binding and phosphorylation of S759 and/or S762. However, binding of MARK2 to β 5 was not disrupted when the two serine residues were mutated to alanine residues, or to glutamic acid residues to mimic phosphoserines (Fig. 4J). These mutations also had no effect on the binding of β 5 to GEF-H1 or p115Rho-GEF.

We conclude that the β 5-SERS region plays a role in the subcellular distribution of the integrin, as the phospho-mimetic replacement of residues 759 and 762 with glutamate residues reduces the clustering of β 5 in FAs.

High cellular tension corresponds with β 5 location to FAs

So far, we learned that cellular tension (Wang et al., 2020; Zuidema et al., 2018), the serine residues in the β 5-SERS region, and the MARK2 and clathrin adaptor proteins, which associate with the β 5 cytoplasmic tail, contribute to the assembly of distinct β 5-containing adhesion complexes. We wondered whether one of these factors could be the main determinant of β 5 clustering in FAs versus FCLs. To this end, we compared the expression levels of talin, MARK2, and clathrin adaptor proteins ARH, Numb and Dab2, and phosphorylation of myosin light chain on serine 19 [phospho-myosin light chain 2 (MCL2)] as an indicator of cellular tension, by western blot in keratinocytes and several colorectal and breast cancer cell lines (Fig. 5A,B). In the colorectal cancer cell lines, the highest level of phospho-MLC was detected in HT29 cells, in which the majority of β 5 localizes in FAs, whereas SW620 cells, which mainly form β 5-containing FCLs, exhibited the lowest level of phospho-MLC. SW480 cells displayed a roughly equal distribution of β 5 in FAs versus FCLs and indeed showed an intermediate level of phospho-MLC. A similar trend was observed for the breast cancer cells MCF7 and MDA-MB-231 (Figs 1 and 5A,B). Thus, a connection between the phospho-MLC levels and the subcellular distribution pattern of integrin β 5 could be observed for both colon and breast cancer cell lines. However, when all the colon and breast cancer cell lines were taken together, this relationship was less clear. To confirm that cellular tension also regulates the β 5 subcellular distribution in SW480 cells, we transfected these cells with a constitutively active RhoA mutant (RhoV14) and observed that β 5 localized almost exclusively in FAs in these cells (Fig. 4C,D), in line with our previous findings in keratinocytes (Wang et al., 2020; Zuidema et al., 2018).

The finding that GEF-H1 is a major integrin β 5 interactor, raised the possibility that the microtubule network is involved in the regulation of β 5 localization. To test this possibility, we treated PA-JEB/ β 4 cells with nocodazole and determined the localization of β 5 within FAs and FCLs. Disruption of microtubules resulted in a significant shift in the localization of β 5 from FCLs to FAs (Fig. 5E–G). Since microtubule disruption has been shown to enhance contractility (Fig. S4A) through activating the RhoA-specific GEF activity of GEF-H1 (Chang et al., 2008), the redistribution of integrin β 5 could be a result of GEF-H1 activation




Fig. 3. Serine 759 and 762 are involved in regulating the localization of integrin $\beta 5$. (A–C) Integrin $\beta 5$ containing S759/762E or S759/762A mutations (A) were expressed in $\beta 5$ -deficient PA-JEB/ $\beta 4$ keratinocytes and the subcellular distribution of $\beta 5$ was compared to $\beta 5$ -deficient keratinocytes expressing wild-type (WT) $\beta 5$. Merged images show integrin $\beta 5$ (green), vinculin (B) or clathrin (C) (red), actin (blue) and the cell nuclei (cyan). (D,E) Analysis of wild-type versus mutant integrin $\beta 5$ clustering in FAs or FCLs. (F–I) PA-JEB/ $\beta 4$ keratinocytes were grown in 10% FCS-supplemented DMEM culture medium overnight and then treated with 5 nM calyculin A (Cal.A) or DMSO (vehicle control) for 30 min prior to fixation. Merged images show integrin $\beta 5$ (green), vinculin (F) or clathrin (H) (red), actin (blue) and the cell nuclei (cyan), quantifications of $\beta 5$ clustering in FAs or FCLs are shown in G,I. (J,K) Analysis of integrin $\beta 5$ clustering in FAs or FCLs in PA-JEB keratinocytes after treatment with Cal.A. Representative confocal microscopy images are shown in Fig. S3. Scale bars: 20 μ m. Data were obtained from three independent experiments. Total cells analyzed per condition: 109 (WT), 116 (S>E), 103 (S>A) (D), 81 (WT), 77 (S>E), 101 (S>A) (E), 126 and 123 (G), 111 and 101 (I), 106 and 102 (J), 115 and 109 (K). **** P <0.0001 (Mann–Whitney U -test). Box plots range from the 25th to 75th percentile; central line indicates the median; whiskers show smallest to largest value.




Fig. 4. See next page for legend.

Fig. 4. MARK2 regulates the localization of integrin $\beta 5$. (A,B) Immunoprecipitations of integrin $\beta 5$ and $\beta 6$ were performed using 5HK2 and 5HK1 antibodies, respectively, in PA-JEB/ $\beta 4$ (A) or HaCaT (B) keratinocytes. Volcano plots show proteins enriched in integrin $\beta 5$ versus $\beta 6$ samples. The logarithmic ratio of protein LFQs were plotted against negative logarithmic P -values of a two-sided two samples t -test. The hyperbolic curve separates significantly enriched proteins from common binders (FDR, 0.05; $n=3$). Proteins discussed here are highlighted in green. (C) Western blots (IB) of normal rabbit serum (–) and integrin $\beta 5$ and $\beta 6$ immunoprecipitations (IP) to validate some of the $\beta 5$ interactors identified by mass spectrometry. MARK2 isoforms have a molecular mass of 77–88 kDa. Representative of two repeats. (D) Representative western blot showing siRNA-mediated knockdown of MARK2 (siMARK2) in PA-JEB/ $\beta 4$ keratinocytes. Quantifications of signal intensities normalized to GAPDH levels are shown ($n=3$; bars show mean \pm s.d.). Western blots of MARK2 expression were performed in parallel to the immunofluorescence analysis shown in E–H. (E–H) Analysis of integrin $\beta 5$ clustering in FAs (E,G) or FCLs (F,H) in control versus MARK2-depleted PA-JEB/ $\beta 4$ keratinocytes. Merged images show integrin $\beta 5$ (green), vinculin (E) or clathrin (F) (red), actin (blue) and the cell nuclei (cyan). Scale bars: 20 μ m. Quantifications of $\beta 5$ clustering in FAs or FCLs are shown in G,H. Data were obtained from three independent experiments. Total cells analyzed per condition: 60 (control), 40 (siMARK2) (G), 122 (control), 105 (siMARK2) (H). (I) Quantifications of integrin $\beta 5$ wild-type versus $\beta 5$ -S759/762E clustering in FAs. Data were obtained from three independent experiments. Total cells analyzed per condition: 136 [wild type (WT), control], 125 (WT, siMARK2), 118 (S759/762E, control), 140 (S759/762E, siMARK2). **** $P<0.0001$; ns, not significant (Mann–Whitney U test). Box plots range from the 25th to 75th percentile; central line indicates the median; whiskers show smallest to largest value. (J) Western blots of integrin $\beta 5$ immunoprecipitations to validate if previously defined $\beta 5$ interactors, MARK2, GEF-H1 and p115-Rho-GEF still associate with wild-type and integrin $\beta 5$ mutants. The black arrow indicates the position of immunoprecipitated MARK2. Representative of three repeats. SE, S759/762E; SA, S759/762A; WCL, whole-cell lysate.

following release from destabilized microtubules. We further tested whether the phospho-mimetic or phospho-inhibitory integrin $\beta 5$ mutant would respond to nocodazole and found neither of their localizations were altered by nocodazole treatment, suggesting these mutations impaired the ability of integrin $\beta 5$ to sense the change on contractility induced by microtubule interruption.

Because it has been shown that MARK2 can phosphorylate GEF-H1 at S886 and inhibit the RhoA-specific GEF activity (Yamahashi et al., 2011), we depleted MARK2 in PA-JEB and PA-JEB/ $\beta 4$ keratinocytes. Surprisingly, we found that rather than decreasing GEF-H1 phosphorylation, the depletion of MARK2 increased the level of GEF-H1 phosphorylation in both PA-JEB and PA-JEB/ $\beta 4$ keratinocytes (Fig. S4F). Likewise, we observed an increase in the phosphorylation of GEF-H1 after treatment of these cells with calyculin A (Fig. S4F). These data indicate that in PA-JEB and PA-JEB/ $\beta 4$ keratinocytes MARK2 does not regulate the localization of integrin $\beta 5$ through phosphorylation of GEF-H1 at S886.

In summary, the amount of cellular tension is indicative of the localization of integrin $\beta 5$, and this could be modulated by microtubule dynamics and GEF-H1.

Integrin $\beta 5$ promotes cell proliferation both in FAs and FCLs

The integrin $\beta 5$ plays a role in breast cancer and osteosarcoma cell proliferation (Bianchi-Smiraglia et al., 2013; Lock et al., 2018). Here, we analyzed the role of integrin $\beta 5$ in cell proliferation of SW620, HT29 and SW480 colorectal cancer cells, in which $\beta 5$ localizes predominantly in FCLs, FAs or is distributed equally in both adhesions, respectively. Because none of these cell lines express the integrin $\beta 3$ subunit (Fig. S5A), we used the integrin $\alpha V\beta 3/\alpha V\beta 5$ antagonist cilengitide as a tool to inhibit $\alpha V\beta 5$ function. The optimal concentration for inhibition was determined for each cell line by assessing the ability of cilengitide to inhibit the clustering of $\beta 5$

(Fig. 6A). Cell proliferation was determined by Crystal Violet staining, and revealed a significant decrease in proliferation of all three cell lines after inhibition of $\beta 5$ with cilengitide (Fig. 6B). This result was confirmed using integrin $\beta 5$ -knockout SW620 and HT29 cell lines, which also showed a decreased proliferation compared to the wild-type cells (Fig. 6C–F). From these results, we conclude that integrin $\beta 5$ promotes colorectal cancer cell proliferation regardless of its localization in FCLs or FAs.

Remarkably, inhibition of vitronectin binding by inhibition or deletion of integrin $\beta 5$ resulted in a drastic change in phenotype, as we observed that $\beta 5$ -deficient and cilengitide-treated SW620 cells grew on top of each other, in contrast to the control cells, which mainly formed a 2D monolayer (Fig. S5B; Fig. 6G). Possibly, the lack of cell adhesion to vitronectin led to the formation of more and/or stronger cell–cell contacts and subsequent growth of cells in three dimensions. Knockout of integrin $\beta 5$ in HT29 cells also produced a dramatic change in phenotype; after 5 days in culture these cells showed reduced spreading with no actin stress fibers or FAs, and were more scattered compared to the wild-type cells (Fig. S5C,D). These phenotypical changes could be rescued to some extent by re-expression of integrin $\beta 5$ (Fig. S5D,E). Unfortunately, the integrin $\beta 5$ rescued cell lines displayed very high intracellular levels of $\beta 5$ and therefore did not exactly resemble the wild-type cells (Fig. S5F). We wondered whether the changes in cell proliferation and morphology upon inhibition or deletion of integrin $\beta 5$ could be driven by altered intracellular signaling pathways or by defective adhesion. Comparing the levels of phospho-Akt (antibody recognizes phosphorylated Akt1–Akt3), phospho-MAPK (phospho-ERK1/2; ERK1 and ERK2 are also known as MAPK3 and MAPK1, respectively), and phospho-FAK (FAK is also known as PTK2) in HT29 and SW620 wild-type, $\beta 5$ -deficient and rescue cells (Fig. S5F) revealed no obvious changes in phospho-Akt or phospho-MAPK levels between integrin $\beta 5$ -deficient and -proficient cells. The $\beta 5$ -deficient HT29 cells exhibited lower levels of phospho-FAK than their wild-type form; however, phospho-FAK levels remained low in $\beta 5$ rescue cells. In addition, we made use of U251MG cells, which have a subcellular $\beta 5$ distribution comparable to that of HT29 (Fig. S1), and observed reduced phospho-FAK levels in $\beta 5$ -deficient U251MG cells (Fig. S5F). Unfortunately, the U251MG rescued cell line also showed very high intracellular levels of integrin $\beta 5$, and thus could not be considered as a proper control in this experiment (Fig. S5F). Nevertheless, we can conclude that deletion of $\beta 5$ hardly affects Akt and MAPK signaling in HT29, SW620 and U251MG cells. Deletion of $\beta 5$ might result in reduced phosphorylation of FAK, which seems more prominent in cells in which $\beta 5$ localizes in FAs. Because we did not observe disrupted signaling pathways in both SW620 and HT29 $\beta 5$ -deficient cells, we hypothesized that the impaired proliferation of these cell lines is most likely caused by defective adhesion to and spreading on vitronectin. Indeed, the proliferation rate of integrin $\beta 5$ -deficient SW620 cells was identical to wild-type cells when cells were grown on collagen-coated plates (Fig. 6H). Similar results were obtained for wild-type and integrin $\beta 5$ -deficient HT29 cells grown on collagen, where the $\beta 5$ -deficient cells even grew slightly faster than the wild-type cells (Fig. 6I).

Taken together, integrin $\beta 5$ promotes colorectal cancer cell proliferation by mediating adhesion and cell spreading on vitronectin-coated surfaces and plays this role regardless of its localization in FAs or FCLs.

FAs form first during early cell–ECM adhesion

The main function of integrin $\beta 5$ is to adhere to vitronectin. We wondered whether integrin $\beta 5$ mediates adhesion to vitronectin




Fig. 5. See next page for legend.

Fig. 5. Actomyosin contractility regulates integrin $\beta 5$ subcellular distribution. (A) Representative western blots of integrin adaptor proteins, MARK2, and phosphorylated myosin light chain (MLC) in PA-JEB/ $\beta 4$ keratinocytes, colorectal cancer cells (HT29, SW480, SW620) and breast cancer cells (MCF7, MDA-MB-231). The medians of the percentage values of $\beta 5$ in FAs (quantified from Figs 1C, 3G) are indicated below. (B) Quantifications of signal intensities normalized to GAPDH levels are shown ($n=3$; bars show mean \pm s.d.). (C,D) SW480 transfected with RhoV14 (constitutively active) mutant. Merged images show RhoV14 positive cells in green, integrin $\beta 5$ (red), and vinculin (C) or clathrin (D) (blue), and the cell nuclei (cyan). RhoV14+ cells are indicated with a green dashed line in the integrin $\beta 5$ channel. Scale bars: 20 μ m. (E–G) Analysis of integrin $\beta 5$ clustering in FAs or FCLs in DMSO (control) versus nocodazole-treated PA-JEB/ $\beta 4$ keratinocytes. (E) Merged images show integrin $\beta 5$ (green), vinculin or clathrin (red), actin (blue) and the cell nuclei (cyan). Scale bars: 20 μ m. (F,G). Quantification of $\beta 5$ clustering in FAs or FCLs. Data were obtained from three independent experiments. Total cells analyzed per condition: 60 (DMSO) and 75 (Noco) (F), and 92 (DMSO) and 75 (Noco) (G). **** $P<0.0001$ (Mann–Whitney U test). Box plots range from the 25th to 75th percentile; central line indicates the median; whiskers show smallest to largest values.

differently in FAs versus FCLs. To address this, the assembly of $\beta 5$ -containing FCLs was analyzed by seeding SW620 cells on vitronectin-coated coverslips and staining cells 1, 2, 4, 8 and 24 h after cell seeding. We observed FA formation during early cell adhesion, although $\beta 5$ at this time point showed a dispersed localization pattern (Fig. 7A). After 2–4 h, $\beta 5$ formed larger structures that colocalized with clathrin molecules but not with vinculin, indicating the exclusive localization of $\beta 5$ to FCLs (Fig. 7A,B). Of interest, cell spreading is associated with a decrease in Rho activity, which is in agreement with our findings that $\beta 5$ -containing FCLs are formed when cellular tension is low (Ren et al., 1999). Between 2–8 h after cell seeding, only small FAs could be detected in SW620 cells. After 24 h, both $\beta 5$ -containing FAs and FCLs could be observed, with SW620 cells favoring the formation of FCLs (Fig. 7A,B). To gain more insight into how integrin $\beta 5$ -containing FCLs play a role in cell–ECM adhesion, we compared integrin $\beta 5$ wild-type and deficient SW620 cells in short (1.5 h) and long-term (4 h) adhesion assays. In the short-term adhesion assay, adhesion to vitronectin only showed a minor decrease in $\beta 5$ -deficient cells compared to wild-type control cells (Fig. 7C). This effect was increased when cells adhered to vitronectin for 4 h (Fig. 7D).

In contrast to SW620 cells, HT29 cells formed $\beta 5$ -containing FAs during early cell adhesion (Fig. 8A). Colocalization of $\beta 5$ with clathrin structures could also be observed for the first time 2–4 h after cell seeding (Fig. 8B). Adhesion to vitronectin could be observed in both short- and long-term adhesion assays (Fig. 8C,D).

In conclusion, both $\beta 5$ -containing FAs and FCLs mediate adhesion to vitronectin, albeit with different dynamics.

DISCUSSION

Integrin $\alpha V\beta 5$ has a unique property – it can localize both in FAs and FCLs. Here, we studied the molecular mechanisms that control the subcellular distribution of integrin $\alpha V\beta 5$ and investigated whether the function of $\beta 5$ depends on its localization. Clathrin adaptor proteins, including ARH, Dab2 and Numb, are required for the formation of $\beta 5$ -containing FCLs and contain binding sites on the $\beta 5$ cytoplasmic domain that overlap with that of talin (Lock et al., 2018; Zuidema et al., 2018; Calderwood et al., 2003). Our peptide pulldown and BioID experiments show that $\beta 5$, but not $\beta 1$ and $\beta 3$, bind to Numb and ARH. In support of this, we were unable to detect binding of $\beta 1$ and $\beta 3$ to ARH and Numb by MST using the same concentration range at which binding of $\beta 5$ could be detected.

Additionally, the measurements show that the affinity of $\beta 5$ for ARH ($K_d=5.6\pm 1.4$ μ M; mean \pm s.d.) and Numb ($K_d=28.5\pm 7.7$ μ M) is higher than that for the THD1 ($K_d=41.7\pm 9.5$ μ M). However, THD1 bound with a slightly higher affinity to the $\beta 5$ than to the $\beta 1$ or $\beta 3$ cytoplasmic domain.

It is important to mention that MST measurements to determine protein-binding affinities were performed with purified *in vitro* synthesized integrin β tails and recombinant THD1, whereas in living cells and total cell lysates used in BioID and peptide pulldown experiments, respectively, other proteins are present that can interact with full-length talin and stabilize its (proximity) interaction with the integrin β cytoplasmic domains. Of interest, talin and kindlin-1/2 cooperate to activate integrins by forming a ternary complex with the β cytoplasmic domain (Ma et al., 2008; Bledzka et al., 2012; Haydari et al., 2020; Theodosiou et al., 2016; Ye et al., 2013; Moser et al., 2008). Because kindlin-1/2 has a higher binding affinity for $\beta 1$ than $\beta 5$, we cannot exclude a (minor) role of kindlin-1/2 in determining the subcellular localization of $\beta 1$ versus $\beta 5$, as it might reinforce the interaction between $\beta 1$ and talin in FAs. ARH is highly expressed in keratinocytes compared to the human cancer cell lines, where Dab2 and Numb might play a more prominent role in regulating the subcellular distribution of $\beta 5$.

In contrast to $\beta 1$, $\beta 3$ and $\beta 5$ did not bind kindlin-1/2 in the peptide pulldown experiments, but interacted strongly with SNX17. Because SNX17 and kindlin share the same binding site on the $\beta 1$ cytoplasmic domain (Böttcher et al., 2012), it is possible that in the peptide pulldown experiments, which were carried out using whole cell lysates from RAC-11P cells, these proteins compete with each other for binding to the different cytoplasmic domain peptides, and that a higher affinity of $\beta 1$ for kindlin-1/2 (Fig. S2) prevents the binding of $\beta 1$ to SNX17 in the peptide pulldown experiments. However, this may only be pertinent when the amount of cytoplasmic domain peptides has been limited. Consistent with the results of the pulldown experiments, MST measurements revealed that $\beta 1$ binds kindlin-2 with a much higher affinity than $\beta 3$ and $\beta 5$.

Taken together, the interactions between the integrin β subunits and their adaptor proteins might result in the distinct subcellular distribution patterns of the integrin receptors.

An additional level of regulation of the integrin $\beta 5$ localization could be accomplished by phosphorylation of the SERS region. Site-directed mutagenesis of the $\beta 5$ S759/S762 to phosphoserine-mimicking glutamate residues resulted in increased localization of $\beta 5$ in FCLs. Previous studies reported that PAK4 binds $\beta 5$ -SERS and regulates its phosphorylation (Li et al., 2010; Zhang et al., 2002), although $\beta 5$ was not identified in the PAK4 interactome (Zhao et al., 2017) and a recent study reports that PAK4 does not phosphorylate $\beta 5$ (Alfonzo-Méndez et al., 2022). We identified PAK2, PAK3 and PAK6 proteins in proximity to the integrin subunits $\beta 3$, $\beta 4$ and $\beta 5$ (Zuidema et al., 2018; Te Molder et al., 2020), but did not find an interaction between $\beta 5$ and any of the PAK proteins. Instead, we identified the serine/threonine-protein kinase MARK2 as a $\beta 5$ -associated protein and demonstrated that MARK2 promotes clustering of wild-type $\beta 5$ in FCLs, but not that of the $\beta 5$ -S759/762E mutant, which is already predominantly localized in FCLs. The finding that a disruptive S>A mutant of the SERS region did not impair the assembly of $\beta 5$ -containing FCLs and these adhesion structures can be formed independently of FAs (Zuidema et al., 2018; Lock et al., 2018) indicates that $\beta 5$ does not need to be phosphorylated to reside in FCLs. Therefore, it would not be expected that $\beta 5$ phosphorylation has a major role in its redistribution. In line with this, calyculin A treatment only led to a minor redistribution of the integrin. Unfortunately, efforts to




Fig. 6. See next page for legend.

Fig. 6. Integrin $\beta 5$ promotes colorectal cancer cell proliferation.

(A) Inhibition of $\beta 5$ clustering by cilengitide treatment in the indicated cell lines. Cells were fixed after 3 days of treatment and $\beta 5$ (green in merge) and vinculin (magenta) were visualized using confocal microscopy. Cell nuclei are shown in blue. Scale bars: 20 μm . (B) Cells were seeded on day 0 and proliferation was measured from day 1–5 in cells with or without cilengitide (added at day 1). (C,E) FACS plots showing the expression of $\beta 5$ in SW620 (C) and HT29 (E) wild-type (WT) and $\beta 5$ knockout cells. Cells stained with a secondary PE-conjugated antibody only were used as negative control ($n=2$). (D,F) Proliferation of SW620 and HT29 wild-type and $\beta 5$ knockout cells. (G) Representative IF images showing integrin $\beta 5$ (green in merge), vinculin (red), actin (blue), nuclei (cyan) in SW620 wild-type, $\beta 5$ -deficient, and cilengitide-treated cells that were cultured for 5 days on coverslips prior to fixation. Scale bars: 100 μm . (H,I) Proliferation of SW620 (H) and HT29 (I) wild-type and $\beta 5$ knockout cells on 3.2 $\mu\text{g ml}^{-1}$ collagen. Results shown represent mean \pm s.d. of three biological replicates, of which each experiment was performed in triplicate. * $P<0.05$ (two-sided unpaired Student's *t*-test).

demonstrate that MARK2 regulates $\beta 5$ localization through its function as a kinase that phosphorylates $\beta 5$ S759/762 have been unsuccessful – neither through mass spectrometry analysis of $\beta 5$ immunoprecipitates prepared from calyculin A-treated cells, nor *in vitro* kinase assays performed with $\beta 5$ immunoprecipitates (which has been shown to contain MARK2; Fig. 4C, data not shown) were we able to detect the phosphorylation of $\beta 5$ at Ser-759/762.

In line with our previous findings (Wang et al., 2020; Zuidema et al., 2018), we observed that $\beta 5$ clustering in FAs is favored in cells that express constitutively active RhoA and that the localization of $\beta 5$ in different cancer cells is positively correlated with the amount of cellular tension. GEF-H1 is a microtubule-associated Rho-GEF that couples microtubule dynamics to cell contractility (Joo and Olson, 2021). GEF-H1 is inactive when bound to microtubules and becomes activated after being released from microtubules upon treatment with the microtubule-depolymerizing drug nocodazole (Krendel et al., 2002). The data that nocodazole inhibits the localization of $\beta 5$ in FCLs and increased cell tension (Fig. 5E–G) suggests an important role of microtubule dynamics in determining the subcellular localization of $\beta 5$. Previously, it was shown that MARK2 can phosphorylate GEF-H1 at S886 and that subsequent phosphorylation of this serine residue inhibits the activity of GEF-H1 by inducing its binding to microtubules (Yamahashi et al., 2011). However, knockdown of MARK2 in PA-JEB and PA-JEB/ $\beta 4$ keratinocytes did not decrease the phosphorylation of GEF-H1, but in fact increased its phosphorylation. A role of this protein in regulating the subcellular localization of $\beta 5$ through phosphorylation of GEF-H1 at S886 therefore seems unlikely.

In addition to MARK2 and GEF-H1, we identified several other microtubule-associated proteins as $\beta 5$ -interacting proteins, including kinesin-1, EB1, HOOK2 and NUDC, and these proteins might play a role in regulating microtubule-based trafficking of $\beta 5$. The impaired ability of integrin $\beta 5$ -S759/762E and -S759/762A mutants to respond to nocodazole treatment (Fig. S4B–E) might be due to disrupted interactions of these microtubule-related proteins to the mutated residues.

To address whether the localization of $\beta 5$ in FAs versus FCLs differentially regulates its function, we selected three colorectal cancer cell lines that contain $\beta 5$ mainly in FAs (HT29), in FCLs (SW620) or in roughly equal levels in both adhesion complexes (SW480). All cell lines showed significantly reduced proliferation after inhibition or deletion of $\beta 5$. It has been reported that depletion of $\beta 5$ does not affect the G1, S, and G2 cell cycle phases (Bianchi-Smiraglia et al., 2013; Lock et al., 2018). Knockdown of $\beta 5$ in breast cancer cells was accompanied by decreased FAK and ERK signaling (Bianchi-Smiraglia et al., 2013); while we also observed decreased

levels of phosphorylated FAK, mainly in $\beta 5$ -deficient HT29 and U251MG, we did not detect obvious changes in ERK activity. Lock et al. observed $\beta 5$ in retraction fibers that lack vinculin and proposed a role for $\beta 5$ in ‘reticular adhesions’ during mitosis, which would offer dividing cells sites of ECM attachment when FAs disassemble (Lock et al., 2018). At the same time, other studies show that the integrin αV and $\beta 1$ subunits also remain present at cell–ECM contact sites after disassembly of FAs during mitosis (Dix et al., 2018; Chen et al., 2022), indicating that reticular adhesions or FCLs do not exclusively mediate adhesion during mitosis. Based on our data, we conclude that $\beta 5$, both in FAs and FCLs, promotes cell proliferation by mediating adhesion to vitronectin, as impaired cell proliferation caused by inhibition or deletion of $\beta 5$ could be rescued by culturing $\beta 5$ -deficient cells on collagen-coated plates. Therefore, the impaired proliferation that we observed was caused by a general adhesion defect to vitronectin and was not achieved by one particular $\beta 5$ -containing adhesion complex. Both $\beta 5$ -containing FAs and FCLs mediate adhesion to vitronectin, although the complexes are formed with different dynamics – FAs are assembled earlier than FCLs and are therefore most likely more important in mediating early cell adhesion and spreading on vitronectin.

Based on our findings, we conclude that the amount of cellular tension regulates the subcellular distribution of $\beta 5$. Interestingly, a recent study demonstrates that the formation of clathrin plaques is regulated by alternative splicing of exon 31 of the clathrin heavy chain gene (CLTC), resulting in the inclusion of a 7-amino-acid sequence within the trimerization domain of the clathrin heavy chain (Moulay et al., 2020). Cells that usually would lack clathrin plaques were able to form them after modulating the splicing of exon 31 (Moulay et al., 2020). These findings raise the question of whether certain cell types are genetically programmed to assemble FCLs. In addition, it would be of interest to study the first event in the formation of FCLs, which could be the frustrated endocytosis of integrins, as we and others have proposed (Zuidema et al., 2020; Baschieri et al., 2018; Zuidema et al., 2018). Alternatively, there could be a cell intrinsic mechanism that starts the formation of FCLs, to which cell surface receptors are subsequently recruited to stabilize these structures by providing anchoring to the ECM. Further investigation will be needed to address these questions.

In conclusion, integrin $\beta 5$ promotes cancer cell proliferation by mediating adhesion to vitronectin. This role of $\beta 5$ can be accomplished in FAs as well as in FCLs. Integrin $\beta 5$ clustering in FCLs is promoted when cellular tension is low and is likely mediated by its interaction with ARH and phosphorylation of its SERS region. In contrast, high actomyosin contractility favors the assembly of $\beta 5$ -containing FAs.

MATERIALS AND METHODS

Reagents

Primary antibodies used are listed in Table S4. Secondary antibodies were as follows: goat anti-rabbit-IgG conjugated to Alexa Fluor 488, goat anti-mouse-IgG conjugated to Alexa Fluor 488, goat anti-mouse-IgG conjugated to Texas Red, goat anti-mouse-IgG conjugated to Alexa Fluor 568, donkey anti-rabbit-IgG conjugated to Alexa Fluor 594, goat anti-rabbit-IgG conjugated to Alexa Fluor 647, and goat anti-mouse-IgG conjugated to Alexa Fluor 647 (Invitrogen), PE-conjugated donkey anti-rabbit-IgG antibody (Biolegend #406421), stabilized HRP-conjugated goat anti-mouse-IgG and HRP-conjugated goat anti-rabbit-IgG (Bio-Rad). A conjugated streptavidin-HRP (1:1000; GE Healthcare #RPN1231) antibody was used for detection of biotinylated proteins. Calyculin A (#9902) was from Cell Signaling Technology and nocodazole from Sigma-Aldrich.




Fig. 7. Integrin $\beta 5$ in clathrin lattices mediates adhesion to vitronectin ~4 h after cell seeding. (A,B) SW620 cells were seeded on vitronectin-coated coverslips and fixed at the indicated time points. Representative immunofluorescence images showing integrin $\beta 5$ (green in merge), vinculin (A) or clathrin (B) (red in merge), actin in blue, and the cell nuclei in cyan. Scale bars: 20 μ m. Representative images are shown of two independent experiments performed in duplicate. (C,D) Adhesion assay performed 1.5 h (C) and 4 h (D) after seeding SW620 wild-type (WT) and $\beta 5$ knockout cells on vitronectin (VN) (three biological replicates; each experiment in triplicate; bars show mean \pm s.d.). ** $P < 0.01$ (two-sided unpaired Student's t -test).




Fig. 8. Integrin $\beta 5$ in focal adhesions mediates early adhesion to vitronectin. (A,B) HT29 cells were seeded on vitronectin-coated coverslips and fixed at the indicated time points. Representative immunofluorescence images show integrin $\beta 5$ (green in merge), vinculin (A) or clathrin (B) (red in merge), actin in blue, and the cell nuclei in cyan. Scale bars: 20 μ m. Representative images are shown of two independent experiments performed in duplicates. (C,D) Adhesion assay performed 1.5 h (C) and 4 h (D) after seeding HT29 wild-type (WT) and $\beta 5$ knockout cells on vitronectin (VN) (three biological replicates; each experiment in triplicate; bars show mean \pm s.d.). * $P < 0.05$ (two-sided unpaired Student's *t*-test).

Cell lines

Immortalized keratinocytes were isolated from a patient with pyloric atresia associated with junctional epidermolysis bullosa (PA-JEB), as published elsewhere (Schaapveld et al., 1998). The derivation of this cell line was done for diagnostic purposes, thus the research conducted using these cells was exempt of the requirement for ethical approval. PA-JEB/β4 keratinocytes stably expressing integrin β4 were generated by retroviral transduction, as described previously (Sterk et al., 2000). Cells were maintained in serum-free keratinocyte medium (KGM; Invitrogen) supplemented with 50 μg ml⁻¹ bovine pituitary gland extract, 5 ng ml⁻¹ EGF and antibiotics (100 units ml⁻¹ streptomycin and 100 units ml⁻¹ penicillin).

RAC-11P (Sonnenberg et al., 1993) and A549, HT29, SW480, SW620, and U251MG cell lines, obtained from the American Type Culture Collection, were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% heat-inactivated FCS and 100 units ml⁻¹ each of streptomycin and penicillin (Sigma).

MCF7 and MDA-MB-231 cell lines were obtained from the research group of Lodewyk F. A. Wessels (The Netherlands Cancer Institute, Div. of Molecular Carcinogenesis, Amsterdam) and authenticated by suppliers using short tandem repeat profiling (Jastrzebski et al., 2018). MCF7 cells are maintained in DMEM and MDA-MB-231 in RPMI medium, both supplemented with 10% heat-inactivated FCS and antibiotics. All cells were cultured at 37°C in a humidified, 5% CO₂ atmosphere.

Transient transfection

MARK2 (M-004260-02-0010) siGENOME SMARTpool siRNAs were purchased from Dharmacon. The cDNA encoding constitutively active [LZRS-IRES-GFP-RhoA(V14)] RhoA was kindly provided by Jacques Neefjes (Leiden University Medical Center, Dept. of Cell and Chemical Biology, The Netherlands). Cells were transiently transfected by using 20 μl ml⁻¹ Lipofectamine[®] 2000 (Invitrogen) and 6.5 μg ml⁻¹ cDNA solutions in Opti-MEM. After mixing these solutions 1:1 and incubating for 30 min at room temperature, cells were incubated with the transfection solution overnight.

Generation of integrin β5-deficient cell lines

The target sgRNA against *ITGB5* (exon 3; 5'-ACGGTCCATCAC-CTCTCGGT-3') was cloned into pX330-U6-Chimeric_BB-CBh-hSpCas9 [Addgene plasmid #42230, deposited by Feng Zhang (Cong et al., 2013)]. HT29 and SW620 cells were transfected with this vector in combination with a blasticidin cassette, as previously described (Blomen et al., 2015). Integrin β5-deficient cells were selected by supplementing the culture medium with 4 μg ml⁻¹ blasticidin (Sigma) for 4 days following transfection and a subsequent FACS sort of the β5-negative cell population.

Stable cellular transduction

The generation of pcDNA3-β5-BirA* (R118G) vector, the expression vectors encoding β5^{ex}/β1ⁱⁿ and β5^{ex}/β3ⁱⁿ chimeric integrin subunits were described previously (Zuidema et al., 2018). Point mutants of β5 S759/S762 were generated by site-directed mutagenesis with the PCR-based overlap extension method using Pfu DNA polymerase (Promega) and were subcloned into the BstEII and XbaI sites of the pcDNA3-β5-BirA* (R118G) vector. The DNA fragment encoding the β5 cytoplasmic domain with the 12-amino-acid stretch of β3 (WDTANNPLYKEA) was ordered as a geneblock from Integrated DNA Technology (IDT) and subcloned into the existing HindIII sites. Retroviral vectors containing mutant β5 cDNAs were generated by subcloning the mutant β5 cDNAs into the EcoRI and XhoI restriction sites of the LZRS-MS-IRES-Zeo vector. PA-JEB/β4 keratinocytes expressing different β5 mutants were generated by retroviral transduction.

Flow cytometry

Cells were treated as indicated, trypsinized, and washed in PBS containing 2% FCS, followed by primary antibody incubation for 45 min at 4°C. Then, cells were washed three times in PBS containing 2% FCS and incubated with PE-conjugated secondary antibody for 45 min at 4°C. Next, after subsequent washing steps, cells were analyzed on an Attune NxT (Thermo Fisher Scientific) flow cytometer. For FACS sorting, the desired cell

populations were isolated using a Becton Dickinson FACSaria IIu or Beckman Coulter MoFlo Astrios cell sorter.

Immunofluorescence

PA-JEB/β4 keratinocytes were seeded on glass coverslips and cultured in complete KGM medium for 24 h, and then treated with DMEM plus 10% FCS for 24 h. Other cell lines were seeded on glass coverslips and cultured in DMEM plus 10% FCS. Cells were fixed with 2% paraformaldehyde (PFA) for 10 min, permeabilized with 0.2% Triton X-100 for 5 min, and blocked with PBS containing 2% bovine serum albumin (BSA; Sigma) for at least 30 min. Next, cells were incubated with the primary antibodies for 1 h at room temperature. Cells were washed three times before incubation with the secondary antibodies for 1 h. Additionally, nuclei were stained with DAPI, and filamentous actin was visualized using Alexa Fluor 488 or 647-conjugated phalloidin (Invitrogen). After three washing steps with PBS, the coverslips were mounted onto glass slides in Mowiol. Images were obtained using a Leica TCS SP5 confocal microscope with a 63× (NA 1.4) oil objective.

BioID assay and western blotting

PA-JEB/β4 cells expressing β5-BirA*, β5^{ex}/β1ⁱⁿ-BirA*, or β5^{ex}/β3ⁱⁿ-BirA were grown on 100 mm plates in complete KGM for 24 h, followed by DMEM supplemented with 50 μM biotin (Sigma #B4501) for 24 h. Cells were washed in cold PBS, lysed in RIPA buffer (20 mM Tris-HCl pH 7.5, 100 mM NaCl, 4 mM, 1% NP-40, 0.1% SDS and 0.5% sodium deoxycholate) supplemented with a protease inhibitor cocktail (Sigma), and cleared by centrifugation at 14,000 g for 30 min at 4°C. Lysates were incubated with Streptavidin Sepharose High Performance beads (GE Healthcare) overnight at 4°C. Beads were washed three times with NP40 buffer (20 mM Tris-HCl pH 7.5, 100 mM NaCl, 4 mM EDTA pH 7.5 and 1% NP-40) and twice with PBS, and the isolated biotinylated proteins were eluted in sample buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 12.5 mM EDTA and 0.02% Bromophenol Blue) containing a final concentration of 2% β-mercaptoethanol and denatured at 95°C for 10 min.

Proteins were separated by electrophoresis using a Bolt Novex 4–12% gradient Bis-Tris gels (Invitrogen) or 15% SDS-PAGE gels (made in-house), transferred to Immobilon-P transfer membranes (Millipore Corp) and blocked for at least 30 min in 2% BSA in TBST buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.3% Tween-20). Primary antibody (diluted 1:1000 in 2% BSA in TBST buffer) incubation took place overnight at 4°C. After washing twice with TBST and twice with TBS, blots were incubated for 1 h at room temperature with horseradish peroxidase-conjugated goat anti-mouse-IgG or goat anti-rabbit-IgG (diluted 1:3000 in 2% BSA in TBST buffer). After subsequent washing steps, the bound antibodies were detected by enhanced chemiluminescence using SuperSignal[™] West Dura Extended Duration Substrate (ThermoFisher) or Clarity[™] Western ECL Substrate (Bio-Rad) as described by the manufacturer. Signal intensities were quantified using ImageJ.

Integrin tail peptide pulldowns

Peptide pulldowns were carried out as previously described (Böttcher et al., 2012) with the mouse β1 wild-type cytoplasmic tail peptide (HDRRE-FAKFEKEKMNAKWDGTGENPIYKSAVTTVVNPKYEGK-OH) and a scrambled peptide (EYEFEPDKVDGTGAKGKMAKNEKKFRNYTVH-NIWESRKVAP-OH), mouse β3 wild-type tail peptide (HDRKEFAKFE-EERARAKWDANNPLYKEATSTFTNTITYRG-T-OH), mouse β5 wild-type tail peptide (DRREFAKFQSESRARYEMASNPYLRKPISTHTVD-FAFNKFNKSYNGSVD-OH), β5 Δ8aa tail peptide (DRREFAKFQSE-RSRARYEMASNPYLRKPISTVVNKSNGSVD-OH) and scrambled peptide RYGNAYDPRRVKLSRFFENTNTFDHSSEKAMARKKSNF-DFSVMYQARISPH.

The tail peptides were synthesized *de novo* with a desthiobiotin on the N-terminus, coupled to Dynabeads MyOne streptavidin C1 (10 mg ml⁻¹, Invitrogen) and incubated with RAC-11P cell lysates (prepared with M-PER reagent, Thermo Fisher Scientific) at 4°C with rotation for 4 h. After three washes with wash buffer (M-PER diluted 1:1 with PBS), bound proteins were eluted in 2× Laemmli buffer at 95°C for 5 min and separated on an 8% SDS-PAGE gel.

Recombinant protein production

Production of ARH, Numb-PTB, THD1 and kindlin-2 production for MST measurements

The full-length human ARH gene was cloned into the pETNKL1-6xhis-3C-LIC vector (Luna-Vargas et al., 2011) and 6xhis-ARH protein was produced in BL21(DE3) *E. coli* cells. Cells were grown at 37°C until an optical density at 600 nm (OD₆₀₀) of 0.6 was reached. Temperature was reduced to 30°C and protein was expressed upon induction with 0.4 mM IPTG for 3.5 h. Cells were harvested and resuspended in lysis buffer (20 mM HEPES, pH 7.5, 200 mM NaCl, 1 mM TCEP and 5 µg ml⁻¹ DNase). After sonication, cell debris and insoluble proteins were removed by centrifugation (21,000 *g* for 30 min). 6xhis-ARH was purified from the soluble fraction using nickel Sepharose beads and eluted in 20 mM HEPES, pH 7.5, 200 mM NaCl, 1 mM TCEP and 250 mM imidazole. Fractions containing 6xhis-ARH were further purified on a SEC650 size exclusion column (Bio-Rad), equilibrated with 20 mM HEPES, pH 7.5, 100 mM NaCl and 1 mM TCEP.

A pETNKL1-6xhis-3C-Numb-PTB (20-175) construct was expressed in Rosetta2 (DE3) cells for 18 h at 20°C. Cells were lysed (25 mM Tris-HCl pH 8.0, 10 mM imidazole, 200 mM NaCl, 1 mM TCEP, 5 µg/ml DNase) and sonicated, after which insoluble proteins and cell debris were removed by centrifugation (21,000 *g* for 30 min at 4°C). Soluble lysate was applied to a nickel Sepharose column and beads were washed with wash buffer (lysis buffer without DNase) before protein was eluted in wash buffer supplemented with 250 mM imidazole. The 6xhis tag was cleaved off by his-3C protease during dialysis against 25 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM TCEP, 16 h at 4°C. Elution fractions were pooled, diluted with six volumes of 20 mM HEPES pH 7.5, 1 mM TCEP and applied to a 1 ml Resource S cation-exchange column (Cytiva). Protein was eluted in a NaCl gradient (50–700 mM) in 25 mM HEPES (pH 7.5). 6xhis-Numb-PTB was concentrated and further purified by size-exclusion chromatography (SEC70 column, Bio-Rad) in 25 mM Tris-HCl pH 8.0, 200 mM NaCl and 1 mM TCEP.

pCoofy17-THD1 (1-405) constructs were transformed into Rosetta2(DE3) cells and his-SUMO-THD1 proteins were expressed for 16 h at 20°C after induction with 0.4 mM IPTG. Cells were harvested and resuspended in 25 mM Tris-HCl pH 8.0, 10 mM imidazole, 200 mM NaCl, 1 mM TCEP and 5 µg ml⁻¹ DNase, and lysed by sonication. The soluble lysate fraction was collected after centrifugation (21,000 *g* for 30 min) and applied to nickel Sepharose beads. Beads were washed with 25 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM TCEP and 10 mM imidazole, and proteins were eluted in the same buffer containing 250 mM imidazole. His-Senp2 protease was added to the proteins to remove the SUMO tag and the solutions were dialyzed against 25 mM Tris-HCl pH 8.0, 200 mM NaCl and 1 mM TCEP for 16 h at 4°C. After cleavage, solutions were passed over nickel beads to remove his-SUMO, residual uncleaved his-SUMO-THD1 and his-Senp2 protease. THD1 proteins were further purified by size exclusion chromatography on a S200 Superdex 16/60 column (Cytiva).

Kindlin-2 was expressed and purified as described in Böttcher et al. (2017). Briefly, kindlin constructs were cloned into pCoofy17 (Scholz et al., 2013), which adds an N-terminal His10-Sumo tag and expressed soluble in *E. coli* Rosetta at 18°C overnight. After purification by immobilized-metal affinity chromatography (IMAC) in high-salt TBS buffer (20 mM Tris, pH 7.5, 500 mM NaCl, 1 mM TCEP), the Sumo tag was removed by SenP2 (obtained from MPIB Biochemistry Core Facility) digest overnight and the protein was further purified by SEC using TBS (20 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM TCEP) containing 5% glycerol as running and storage buffer. After the final chromatography, the purity, integrity and identity of recombinant kindlin-2 and talin-1 head domain were controlled by UV spectrum, SDS-PAGE, high-resolution total mass and dynamic light scattering (DLS).

MST measurements

All MST measurements were performed on a Monolith NT.115 red-blue (Nanotemper, Munich, Germany) using premium-coated capillaries to reduce non-specific interaction of the proteins with the glass surface. Both interaction partners (ligand and receptor) were transferred into MST buffer (20 mM Tris-HCl pH 7.5, 200 mM sodium chloride, 1 mM TCEP and

0.05% Tween-20) to avoid artifacts derived from buffer mismatches. 50–200 nM Atto488-labeled integrin-β cytoplasmic tail (synthesized by the MPIB Core Facility) were used as ligands. The measurements were carried out at 10 to 20% LED power and 20 and 40% MST power. Data was analyzed using the MO Affinity Analysis Software (Nanotemper).

Mass spectrometry

HaCat and PA-JEB/β4 keratinocytes were grown to 95% confluence in 15 cm dishes and lysed in 2 ml NP40 lysis buffer. After centrifugation for 60 min at 4°C cells, the supernatants were collected and incubated overnight at 4°C with Protein A Sepharose (GE Healthcare) coupled with antibodies. After washing three times with NP40 lysis buffer, and two times with PBS, bound protein were eluted by heating at 95°C in SDS-PAGE sample buffer and separated on a 4–12% SDS-PAGE gel. The gel was stained with Coomassie Blue, and lanes were excised and then reduced by treating with dithiothreitol and alkylated with iodoacetamide. After digestion with trypsin (mass spectrometry grade; Promega), peptide mixtures were extracted, measured and analyzed as previously described (Wang et al., 2020), with the following exceptions. Peptide mixtures (33% of total digest) were loaded directly onto the analytical column and analyzed by nano-liquid chromatography tandem mass spectrometry (nanoLC-MS/MS) on an Orbitrap Exploris 480 mass spectrometer equipped with a Proxeon nLC1200 system (Thermo Scientific). Solvent A was 0.1% formic acid in water and solvent B was 0.1% formic acid in 80% acetonitrile. Peptides were eluted from the analytical column at a constant flow of 250 nl/min in a 80-min gradient, containing a 64-min linear increase from 7% to 26% solvent B, followed by an 11-min wash at 90% solvent B.

Raw data were analyzed by MaxQuant (version 2.0.1.0; Cox et al., 2014) using standard settings for label-free quantitation (LFQ). MS/MS data were searched against the a Swissprot human database (20,397 entries, release 2021_04) complemented with a list of common contaminants and concatenated with the reversed version of all sequences. LFQ intensities were Log2-transformed in Perseus (version 1.6.14.0) (Tyanova et al., 2016), after which proteins were filtered for at least two out of three valid values in at least one sample group. Differentially expressed proteins were determined using an unpaired, two-tailed Student's *t*-test [thresholds false discovery rate (FDR) 0.05 and S0 0.1].

Proliferation assay

Cells were seeded at a density of 5×10⁴ cells per well in a 96-well plate and treated with cilengitide or DMSO, as indicated in the figure legend. Then cells were fixed with 4% PFA at 1, 2, 3, 4 or 5 days after seeding. After fixation, cells were washed twice with H₂O, stained with Crystal Violet for 30 min at room temperature and washed extensively with H₂O. Cells were air-dried overnight and lysed in 2% SDS, after which the OD value of Crystal Violet at 490 nm was determined using an Epoch microplate reader equipped with Gen5 software. Assays were performed in triplicates and repeated twice.

Adhesion assay

For adhesion assays, 96-well plates were coated with 5 µg ml⁻¹ vitronectin (Sigma, #SRP3186) for 2 h at 37°C. Cells were trypsinized, resuspended in serum-free DMEM, and seeded at a density of 10⁵ cells per well and incubated for 1.5 or 4 h at 37°C. Nonadherent cells were washed away with PBS and the adherent cells were fixed with 4% PFA for 10 min at room temperature, washed twice with H₂O, stained with Crystal Violet for 30 min at room temperature and washed extensively with H₂O. Cells were air-dried overnight and lysed in 2% SDS, after which absorbance was measured at 590 nm on an Epoch microplate reader using Gen5 software. The values were normalized to the control group. Assays were performed in triplicates and repeated twice.

Image analysis and statistical analysis

Image analysis was performed using Fiji (ImageJ) (Schindelin et al., 2012; Schneider et al., 2012). To quantify integrin clustering in FAs (based on vinculin staining) versus FCLs (clathrin staining), background was subtracted in both channels using a bilateral filter and the region of interest (ROI) was selected at the cell periphery. Colocalization of integrin

clusters and FAs or FCLs was determined using the Image Calculator (command 'multiply') on both channels and calculating the area of overlapping clusters as a percentage of the total integrin cluster area per cell using the Analyze Particle function.

Mann–Whitney or two-sided unpaired Student's *t*-test (two-tailed *P* value) was performed using GraphPad Prism (version 7.0c). In figures, statistically significant values are shown as **P*<0.05; ***P*<0.01; ****P*<0.001; *****P*<0.0001. Graphs were made in GraphPad Prism and display data in bars showing mean±s.d. or show all data points represented as box-and-whisker plots, in which the box extends the 25th to 75th percentiles, the middle line indicates the median, and whiskers go down to the smallest value and up to the largest.

Acknowledgements

We thank Marina Glukhova, Simon Goodman, Ulrike Mayer, Jacques Neefjes, Ellen van der Schoot, and NKI colleagues for sharing cells and reagents, and Paul Atherton for critical reading of the manuscript.

Competing interests

The authors declare no competing or financial interests.

Author contributions

Conceptualization: A.Z., W.W., A.S.; Methodology: A.Z., W.W., M.K., O.B.B., L.H., J.A., R.T.B., A.S.; Validation: A.Z., A.S.; Formal analysis: A.Z., W.W., A.S.; Investigation: A.Z., W.W., M.K., O.B.B., L.H., J.A., A.S.; Writing - original draft: A.Z., A.S.; Writing - review & editing: J.A., R.T.B., R.F., A.S.; Visualization: A.Z., A.S.; Supervision: A.S.; Funding acquisition: R.F., A.S.

Funding

This work was supported by the Netherlands Organization for Scientific Research [Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NOW); project number 824.14.010] and the Dutch Cancer Society (project number 12143). O.B.B. and L.H. were supported by the Dutch NWO X-omics Initiative. A.S. and R.F. would like to thank the Alexander von Humboldt Foundation for supporting A.S. during his sabbatical year at the Max Planck Institute. Open access funding provided by Netherlands Cancer Institute. Deposited in PMC for immediate release.

Peer review history

The peer review history is available online at <https://journals.biologists.com/jcs/article-lookup/doi/10.1242/jcs.259465>.

References

- Alfonzo-Méndez, M. A., Sochacki, K. A., Strub, M.-P. and Taraska, J. W. (2022). Dual clathrin and integrin signaling systems regulate growth factor receptor activation. *Nat Commun.* **13**, 905. doi:10.1038/s41467-022-28373-x
- Anthis, N. J., Wegener, K. L., Critchley, D. R. and Campbell, I. D. (2010). Structural diversity in integrin/talin interactions. *Structure* **18**, 1654–1666. doi:10.1016/j.str.2010.09.018
- Askham, J. M., Vaughan, K. T., Goodson, H. V. and Morrison, E. E. (2002). Evidence that an interaction between EB1 and p150Glued is required for the formation and maintenance of a radial microtubule array anchored at the centrosome. *Mol. Biol. Cell* **13**, 3627–3645. doi:10.1091/mbc.e02-01-0061
- Aumais, J. P., Tunstead, J. R., Mcneil, R. S., Schaar, B. T., McConnell, S. K., Lin, S.-H., Clark, G. D. and Yu-Lee, L.-Y. (2001). NudC associates with Lis1 and the Dynein motor at the leading pole of neurons. *The J. Neurosci.* **21**, RC187. doi:10.1523/JNEUROSCI.21-24-j0002.2001
- Aumais, J. P., Williams, S. N., Luo, W., Nishino, M., Caldwell, K. A., Caldwell, G. A., Lin, S.-H. and Yu-Lee, L.-Y. (2003). Role for NudC, a dynein-associated nuclear movement protein, in mitosis and cytokinesis. *J. Cell Sci.* **116**, 1991–2003. doi:10.1242/jcs.00412
- Bai, S. Y., Xu, N., Chen, C., Song, Y.-L., Hu, J. and Bai, C.-X. (2015). Integrin α v β 5 as a biomarker for the assessment of non-small cell lung cancer metastasis and overall survival. *Clin. Respir. J.* **9**, 457–467. doi:10.1111/crj.12163
- Baschieri, F., Dayot, S., Elkhathib, N., Ly, N., Capmany, A., Schauer, K., Betz, T., Vignjevic, D. M., Poincloux, R. and Montagnac, G. (2018). Frustrated endocytosis controls contractility-independent mechanotransduction at clathrin-coated structures. *Nat. Commun.* **9**, 3825. doi:10.1038/s41467-018-06367-y
- Baschieri, F., Porshneva, K. and Montagnac, G. (2020). Frustrated clathrin-mediated endocytosis – causes and possible functions. *J. Cell Sci.* **133**, jcs240861. doi:10.1242/jcs.240861
- Bianchi-Smiraglia, A., Paesante, S. and Bakin, A. V. (2013). Integrin β 5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. *Oncogene* **32**, 3049–3058. doi:10.1038/onc.2012.320
- Bledzka, K., Liu, J., Xu, Z., Perera, H. D., Yadav, S. P., Bialkowska, K., Qin, J., Ma, Y.-Q. and Plow, E. F. (2012). Spatial coordination of kindlin-2 with talin head domain in interaction with integrin beta cytoplasmic tails. *J. Biol. Chem.* **287**, 24585–24594. doi:10.1074/jbc.M111.336743
- Blomen, V. A., Májek, P., Jae, L. T., Bigenzahn, J. W., Nieuwenhuis, J., Staring, J., Sacco, R., Van Diemen, F. R., Olk, N., Stukalov, A. et al. (2015). Gene essentiality and synthetic lethality in haploid human cells. *Science* **350**, 1092–1096. doi:10.1126/science.aac7557
- Böttcher, R. T., Stremmel, C., Meves, A., Meyer, H., Widmaier, M., Tseng, H.-Y. and Fässler, R. (2012). Sorting nexin 17 prevents lysosomal degradation of β 1 integrins by binding to the beta1-integrin tail. *Nat. Cell Biol.* **14**, 584–592. doi:10.1038/ncb2501
- Böttcher, R. T., Veelders, M., Rombaut, P., Faix, J., Theodosiou, M., Stradal, T. E., Rottner, K., Zent, R., Herzog, F. and Fässler, R. (2017). Kindlin-2 recruits paxillin and Arp2/3 to promote membrane protrusions during initial cell spreading. *J. Cell Biol.* **216**, 3785–3798. doi:10.1083/jcb.201701176
- Burridge, K. (2017). Focal adhesions: a personal perspective on a half century of progress. *FEBS J.* **284**, 3355–3361. doi:10.1111/febs.14195
- Calderwood, D. A., Fujioka, Y., De Pereda, J. M., García-Alvarez, B., Nakamoto, T., Margolis, B., Mcglade, C. J., Liddington, R. C. and Ginsberg, M. H. (2003). Integrin β cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. *Proc. Natl. Acad. Sci. USA* **100**, 2272–2277. doi:10.1073/pnas.262791999
- Chang, Y.-C., Nalbant, P., Birkenfeld, J., Chang, Z.-F. and Bokoch, G. M. (2008). GEF-H1 couples nocodazole-induced microtubule disassembly to cell contractility via RhoA. *Mol. Biol. Cell* **19**, 2147–2153. doi:10.1091/mbc.e07-12-1269
- Chen, N. P., Aretz, J. and Fässler, R. (2022). CDK1-cyclin-B1-induced kindlin degradation drives focal adhesion disassembly at mitotic entry. *Nat. Cell Biol.* **24**, 723–736. doi:10.1038/s41556-022-00886-z
- Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A. et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819–823. doi:10.1126/science.1231143
- Cox, J., Hein, M. Y., Lubner, C. A., Paron, I., Nagaraj, N. and Mann, M. (2014). Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. *Mol. Cell Proteomics* **13**, 2513–2526. doi:10.1074/mcp.M113.031591
- Dix, C. L., Matthews, H. K., Uroz, M., McLaren, S., Wolf, L., Heatley, N., Win, Z., Almada, P., Henriques, R., Boutros, M. et al. (2018). The role of mitotic cell-substrate adhesion re-modeling in animal cell division. *Dev. Cell* **45**, 132–145.e3. doi:10.1016/j.devcel.2018.03.009
- Enns, A., Korb, T., Schlüter, K., Gassmann, P., Spiegel, H.-U., Senninger, N., Mitjans, F. and Haier, J. (2005). α v β 5-integrins mediate early steps of metastasis formation. *Eur. J. Cancer* **41**, 1065–1072. doi:10.1016/j.ejca.2004.12.031
- Frank, A., Lainé, J., Moulay, G., Lemerle, E., Trichet, M., Gentil, C., Benkhelifa-Ziyyat, S., Lacene, E., Bui, M. T., Brochier, G. et al. (2019). Clathrin plaques and associated actin anchor intermediate filaments in skeletal muscle. *Mol. Biol. Cell* **30**, 579–590. doi:10.1091/mbc.E18-11-0718
- Gladson, C. L., Dennis, C., Rotolo, T. C., Kelly, D. R. and Grammer, J. R. (1997). Vitronectin expression in differentiating neuroblastic tumors: integrin alpha v beta 5 mediates vitronectin-dependent adhesion of retinoic-acid-differentiated neuroblastoma cells. *Am. J. Pathol.* **150**, 1631–1646.
- Grove, J., Metcalf, D. J., Knight, A. E., Wavre-Shapton, S. T., Sun, T., Protonotarios, E. D., Griffin, L. D., Lippincott-Schwartz, J. and Marsh, M. (2014). Flat clathrin lattices: stable features of the plasma membrane. *Mol. Biol. Cell* **25**, 3581–3594. doi:10.1091/mbc.e14-06-1154
- Haydari, Z., Shams, H., Jahed, Z. and Mofrad, M. R. K. (2020). Kindlin assists talin to promote integrin activation. *Biophys J.* **118**, 1977–1991. doi:10.1016/j.bpj.2020.02.023
- Huang, X., Griffiths, M., Wu, J., Farese, R. V., Jr and Sheppard, D. (2000). Normal development, wound healing, and adenovirus susceptibility in β 5-deficient mice. *Mol. Cell Biol.* **20**, 755–759. doi:10.1128/MCB.20.3.755-759.2000
- Hynes, R. O. (2002). Integrins: bidirectional, allosteric signaling machines. *Cell* **110**, 673–687. doi:10.1016/S0092-8674(02)00971-6
- Jastrzebski, K., Thijssen, B., Kluin, R. J. C., De Lint, K., Majewski, I. J., Beijersbergen, R. L. and Wessels, L. F. A. (2018). Integrative modeling identifies key determinants of inhibitor sensitivity in breast cancer cell lines. *Cancer Res.* **78**, 4396–4410. doi:10.1158/0008-5472.CAN-17-2698
- Jiang, R., Vandal, S., Park, S., Majd, S., Tuzel, E. and Hancock, W. O. (2019). Microtubule binding kinetics of membrane-bound kinesin-1 predicts high motor copy numbers on intracellular cargo. *Proc. Natl. Acad. Sci. USA* **116**, 26564–26570. doi:10.1073/pnas.1916204116
- Joo, E. and Olson, M. F. (2021). Regulation and functions of the RhoA regulatory guanine nucleotide exchange factor GEF-H1. *Small GTPases* **12**, 358–371. doi:10.1080/21541248.2020.1840889
- Kaneko, T., Furuta, K., Oiwa, K., Shintaku, H., Kotera, H. and Yokokawa, R. (2020). Different motilities of microtubules driven by kinesin-1 and kinesin-14 motors patterned on nanopillars. *Sci. Adv.* **6**, eaax7413. doi:10.1126/sciadv.aax7413

- Krämer, H. and Phistry, M. (1996). Mutations in the *Drosophila* hook gene inhibit endocytosis of the boss transmembrane ligand into multivesicular bodies. *J. Cell Biol.* **133**, 1205–1215. doi:10.1083/jcb.133.6.1205
- Krendel, M., Zenke, F. T. and Bokoch, G. M. (2002). Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton. *Nat. Cell Biol.* **4**, 294–301. doi:10.1038/ncb773
- Lampe, M., Vassilopoulos, S. and Merrifield, C. (2016). Clathrin coated pits, plaques and adhesion. *J. Struct. Biol.* **196**, 48–56. doi:10.1016/j.jsb.2016.07.009
- Leyton-Puig, D., Isogai, T., Argenzio, E., Van Den Broek, B., Klarenbeek, J., Janssen, H., Jalink, K. and Innocenti, M. (2017). Flat clathrin lattices are dynamic actin-controlled hubs for clathrin-mediated endocytosis and signalling of specific receptors. *Nat. Commun.* **8**, 16068. doi:10.1038/ncomms16068
- Li, Z., Zhang, H., Lundin, L., Thullberg, M., Liu, Y., Wang, Y., Claesson-Welsh, L. and Strömblad, S. (2010). p21-activated kinase 4 phosphorylation of integrin $\beta 5$ Ser-759 and Ser-762 regulates cell migration. *J. Biol. Chem.* **285**, 23699–23710. doi:10.1074/jbc.M110.123497
- Lock, J. G., Jones, M. C., Askari, J. A., Gong, X., Oddone, A., Olofsson, H., Goransson, S., Lakadamyali, M., Humphries, M. J. and Strömblad, S. (2018). Reticular adhesions are a distinct class of cell-matrix adhesions that mediate attachment during mitosis. *Nat. Cell Biol.* **20**, 1290–1302. doi:10.1038/s41556-018-0220-2
- Lock, J. G., Baschieri, F., Jones, M. C., Humphries, J. D., Montagnac, G., Strömblad, S. and Humphries, M. J. (2019). Clathrin-containing adhesion complexes. *J. Cell Biol.* **218**, 2086–2095. doi:10.1083/jcb.201811160
- Luna-Vargas, M. P., Christodoulou, E., Alfieri, A., Van Dijk, W. J., Stadnik, M., Hibbert, R. G., Sahtoe, D. D., Clerici, M., Marco, V. D., Littler, D. et al. (2011). Enabling high-throughput ligation-independent cloning and protein expression for the family of ubiquitin specific proteases. *J. Struct. Biol.* **175**, 113–119. doi:10.1016/j.jsb.2011.03.017
- Ma, Y. Q., Qin, J., Wu, C. and Plow, E. F. (2008). Kindlin-2 (Mig-2): a co-activator of $\beta 3$ integrins. *J. Cell Biol.* **181**, 439–446. doi:10.1083/jcb.200710196
- Moser, M., Nieswandt, B., Ussar, S., Pozgajova, M. and Fässler, R. (2008). Kindlin-3 is essential for integrin activation and platelet aggregation. *Nat. Med.* **14**, 325–330. doi:10.1038/nm1722
- Moulay, G., Laine, J., Lemaître, M., Nakamori, M., Nishino, I., Caillol, G., Mamchaoui, K., Julien, L., Dingli, F., Loew, D. et al. (2020). Alternative splicing of clathrin heavy chain contributes to the switch from coated pits to plaques. *J. Cell Biol.* **219**, e201912061. doi:10.1083/jcb.201912061
- Nandrot, E. F., Anand, M., Sircar, M. and Finnemann, S. C. (2006). Novel role for $\alpha \beta 5$ -integrin in retinal adhesion and its diurnal peak. *Am. J. Physiol. Cell Physiol.* **290**, C1256–C1262. doi:10.1152/ajpcell.00480.2005
- Ren, X.-D., Kiosses, W. B. and Schwartz, M. A. (1999). Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. *EMBO J.* **18**, 578–585. doi:10.1093/emboj/18.3.578
- Roux, K. J., Kim, D. I., Raida, M. and Burke, B. (2012). A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells. *J. Cell Biol.* **196**, 801–810. doi:10.1083/jcb.201112098
- Sato, Y., Akitsu, M., Amano, Y., Yamashita, K., Ide, M., Shimada, K., Yamashita, A., Hirano, H., Arakawa, N., Maki, T. et al. (2013). The novel PAR-1-binding protein MTCL1 has crucial roles in organizing microtubules in polarizing epithelial cells. *J. Cell Sci.* **126**, 4671–4683. doi:10.1242/jcs.127845
- Schaapveld, R. Q. J., Borradori, L., Geerts, D., Van Leusden, M. R., Kuikman, I., Nievers, M. G., Niessen, C. M., Steenbergen, R. D. M., Snijders, P. J. F. and Sonnenberg, A. (1998). Hemidesmosome formation is initiated by the $\beta 4$ integrin subunit, requires complex formation of $\beta 4$ and HD1/plectin, and involves a direct interaction between $\beta 4$ and the bullous pemphigoid antigen 180. *J. Cell Biol.* **142**, 271–284. doi:10.1083/jcb.142.1.271
- Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B. et al. (2012). Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682. doi:10.1038/nmeth.2019
- Schittenhelm, J., Klein, A., Tatagiba, M. S., Meyermann, R., Fend, F., Goodman, S. L. and Sipos, B. (2013). Comparing the expression of integrins $\alpha \beta 3$, $\alpha \beta 5$, $\alpha \beta 6$, $\alpha \beta 8$, fibronectin and fibrinogen in human brain metastases and their corresponding primary tumors. *Int. J. Clin. Exp. Pathol.* **6**, 2719–2732.
- Schneider, C. A., Rasband, W. S. and Eliceiri, K. W. (2012). NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* **9**, 671–675. doi:10.1038/nmeth.2089
- Scholz, J., Besir, H., Strasser, C. and Suppmann, S. (2013). A new method to customize protein expression vectors for fast, efficient and background free parallel cloning. *BMC Biotechnol.* **13**, 12. doi:10.1186/1472-6750-13-12
- Sonnenberg, A., De Melker, A. A., Martínez De Velasco, A. M., Janssen, H., Calafat, J. and Niessen, C. M. (1993). Formation of hemidesmosomes in cells of a transformed murine mammary tumor cell line and mechanisms involved in adherence of these cells to laminin and kalinin. *J. Cell Sci.* **106**, 1083–1102. doi:10.1242/jcs.106.4.1083
- Sterk, L. M. T., Geuijen, C. A. W., Oomen, L. C. J. M., Calafat, J., Janssen, H. and Sonnenberg, A. (2000). The tetraspan molecule CD151, a novel constituent of hemidesmosomes, associates with the integrin $\alpha 6 \beta 4$ and may regulate the spatial organization of hemidesmosomes. *J. Cell Biol.* **149**, 969–982. doi:10.1083/jcb.149.4.969
- Te Molder, L., Hoekman, L., Kreft, M., Bleijerveld, O. and Sonnenberg, A. (2020). Comparative interactomics analysis reveals potential regulators of $\alpha 6 \beta 4$ distribution in keratinocytes. *Biol. Open* **9**, bio054155. doi:10.1242/bio.054155
- Theodosiou, M., Widmaier, M., Böttcher, R. T., Rognoni, E., Veelders, M., Bharadwaj, M., Lambacher, A., Austen, K., Müller, D. J., Zent, R. et al. (2016). Kindlin-2 cooperates with talin to activate integrins and induces cell spreading by directly binding paxillin. *Elife* **5**, e10130. doi:10.7554/eLife.10130
- Tomasini-Johansson, B. R., Sundberg, C., Lindmark, G., Gailit, J. O. and Rubin, K. (1994). Vitronectin in colorectal adenocarcinoma—synthesis by stromal cells in culture. *Exp. Cell. Res.* **214**, 303–312. doi:10.1006/excr.1994.1262
- Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M. and Cox, J. (2016). The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat. Methods* **13**, 731–740. doi:10.1038/nmeth.3901
- Uhm, J. H., Dooley, N. P., Kyritsis, A. P., Rao, J. S. and Gladson, C. L. (1999). Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. *Clin. Cancer Res.* **5**, 1587–1594.
- Vogetseder, A., Thies, S., Ingold, B., Roth, P., Weller, M., Schraml, P., Goodman, S. L. and Moch, H. (2013). αv -Integrin isoform expression in primary human tumors and brain metastases. *Int. J. Cancer* **133**, 2362–2371. doi:10.1002/ijc.28267
- Walenta, J. H., Didier, A. J., Liu, X. and Krämer, H. (2001). The Golgi-associated hook3 protein is a member of a novel family of microtubule-binding proteins. *J. Cell Biol.* **152**, 923–934. doi:10.1083/jcb.152.5.923
- Wang, W., Zuidema, A., Te Molder, L., Nahidiazar, L., Hoekman, L., Schmidt, T., Coppola, S. and Sonnenberg, A. (2020). Hemidesmosomes modulate force generation via focal adhesions. *J. Cell Biol.* **219**, e201904137. doi:10.1083/jcb.201904137
- Wayner, E. A., Orlando, R. A. and Cheresh, D. A. (1991). Integrins $\alpha v \beta 3$ and $\alpha v \beta 5$ contribute to cell attachment to vitronectin but differentially distribute on the cell surface. *J. Cell Biol.* **113**, 919–929. doi:10.1083/jcb.113.4.919
- Yamashita, Y., Saito, Y., Murata-Kamiya, N. and Hatakeyama, M. (2011). Polarity-regulating kinase partitioning-defective 1b (PAR1b) phosphorylates guanine nucleotide exchange factor H1 (GEF-H1) to regulate RhoA-dependent actin cytoskeletal reorganization. *J. Biol. Chem.* **286**, 44576–44584. doi:10.1074/jbc.M111.267021
- Ye, F., Petrich, B. G., Anekal, P., Lefort, C. T., Kasirer-Friede, A., Shattil, S. J., Ruppert, R., Moser, M., Fassler, R. and Ginsberg, M. H. (2013). The mechanism of kindlin-mediated activation of integrin $\alpha 11 \beta 3$. *Curr. Biol.* **23**, 2288–2295. doi:10.1016/j.cub.2013.09.050
- Zhang, H., Li, Z., Viklund, E.-K. and Strömblad, S. (2002). P21-activated kinase 4 interacts with integrin $\alpha \beta 5$ and regulates $\alpha \beta 5$ -mediated cell migration. *J. Cell Biol.* **158**, 1287–1297. doi:10.1083/jcb.200207008
- Zhao, M., Spiess, M., Johansson, H. J., Olofsson, H., Hu, J., Lehtio, J. and Strömblad, S. (2017). Identification of the PAK4 interactome reveals PAK4 phosphorylation of N-WASP and promotion of Arp2/3-dependent actin polymerization. *Oncotarget* **8**, 77061–77074. doi:10.18632/oncotarget.20352
- Zuidema, A., Wang, W., Kreft, M., Te Molder, L., Hoekman, L., Bleijerveld, O. B., Nahidiazar, L., Janssen, H. and Sonnenberg, A. (2018). Mechanisms of integrin $\alpha 6 \beta 4$ clustering in flat clathrin lattices. *J. Cell Sci.* **131**, jcs221317. doi:10.1242/jcs.221317
- Zuidema, A., Wang, W. and Sonnenberg, A. (2020). Crosstalk between cell adhesion complexes in regulation of mechanotransduction. *Bioessays* **42**, e2000119. doi:10.1002/bies.202000119




Fig. S1. (A,B) IF images of U251MG and A549 cells showing integrin $\beta 5$ (green in merge), vinculin **(A)** or clathrin **(B)** (red in merge), actin (blue), DAPI (cyan). Scale bar, 20 μ m.




Fig. S2. (A) Titration of kindlin-2 (K2) and talin-1 head domain (THD1) to 200 nM ATTO488-labeled integrin β_1 , β_3 , and β_5 cytoplasmic tail peptides (β -CT) to measure affinity using MST ($n \geq 3$). **(B)** Colocalization of the integrin $\beta_5^{\text{ex}}/\beta_3^{\text{in}}$ chimera containing a Y786A mutation in the MD-NxxY motif (green in merge) with vinculin (red; left panel) or clathrin (red; right panel) in β_5 -deficient PA-JEB/ β_4 keratinocytes. Actin is shown in blue. Nuclei are stained with DAPI (cyan). Scale bar, 20 μ m.




Fig. S3. (A) Amino acid sequences of the cytoplasmic domain of wild-type integrin β 1, β 3, β 5 and β 5 carrying mutations surrounding the membrane-proximal NPLY motif. The subcellular distribution of the integrin β subunits in FAs or FCLs is indicated. **(B)** Representative confocal microscopy images show that the integrin β 5 mutant, carrying a substitution of 12 amino acids from β 3 into β 5 (Y766-P777 subst.) localizes predominantly in FCLs in PA-JEB/ β 4 keratinocytes **(C,D)** PA-JEB keratinocytes were grown in 10% FCS-supplemented DMEM culture medium overnight and then treated with 5 nM calyculin A (Cal.A) or DMSO (vehicle control) for 30 min prior to fixation. Merged images show integrin β 5 (green), vinculin **(B,C)** or clathrin **(B,D)** (red), actin (blue) and the cell nuclei (cyan). Scale bar, 20 μ m.




Fig. S4. (A) Representative western blots of phosphorylated myosin light chain (MLC) and GAPDH in PA-JEB/β4 keratinocytes treated with DMSO versus Nocodazole. **(B-E)** Analysis of integrin β5 clustering in FAs **(C)** in β5-deficient keratinocytes expressing wild-type β5, and β5 containing S759/762E or S759/762A mutations. Merged images show integrin β5 (green), vinculin (red), actin (blue) and the cell nuclei (cyan) **(C)**. Scale bar, 20 μm. Quantifications of β5 or β5 mutants clustering in FAs are shown in **(C-E)**. Data were obtained from three independent experiments. Total cells analyzed per condition: 90 (WT, DMSO), 111 (WT, Noco.) **(C)**, 40 (S>E, DMSO), 80 (S>E, Noco.) **(D)**, 65 (S>A, DMSO), 82 (S>A, Noco.) **(E)**. Mann-Whitney U test was performed to determine statistical significance. ****, $P < 0.0001$. Box plots range from the 25th to 75th percentile; central line indicates the median; whiskers show smallest to largest value. **(F)** Representative western blots of phosphorylated GEF-H1, total GEF-H1 and MARK2 in PA-JEB/β4 and PA-JEB keratinocytes treated with or without siMARK2 combined with calyculin A. Integrin β4, β5 and GAPDH served as controls. (n=3).




Fig. S5. (A) FACS plots showing the expression of integrin $\beta 3$ in HT29, SW480, and SW620 cells. HT29 cells stained with a secondary PE-conjugated antibody only were used as negative control ($n=3$). **(B,C)** FACS plots showing the expression of $\beta 5$ in SW620 **(B)** and HT29 **(C)** wild-type, $\beta 5$ knockout and rescued cells. Cells stained with a secondary PE-conjugated antibody only were used as negative control ($n=2-3$). **(D)** HT29 cells were fixed after 5 days and merged images show integrin $\beta 5$ (green), talin (red), actin (blue) and the cell nuclei (cyan). Scale bar, 20 μm . **(E)** Quantifications of the cell area of HT29 wild-type, $\beta 5$ knockout and rescued cells. Data were obtained from three independent experiments. Total cells analyzed per condition: 179 (WT), 161 (KO), 172 (Resc.) Mann-Whitney U test was performed to determine statistical significance. ****, $P < 0.0001$. Box plots range from the 25th to 75th percentile; central line indicates the median; whiskers show smallest to largest value. **(F)** Representative western blots of phosphorylated FAK, MAPK, AKT in wild-type, $\beta 5$ -deficient (KO) and $\beta 5$ rescued (Resc.) cell lines. Quantifications of signal intensities of the phosphorylated proteins normalized to total proteins levels are shown ($n=3$; bars show mean with s.d.).

Table S1. Overview of cells that form integrin $\beta 5$ -containing FCLs

Cells	Adhesion complex	Reference
A375 human melanoma cells A549 human lung carcinoma cells U2OS human osteosarcoma cells CS1 hamster melanoma cells HeLa human cervical carcinoma cells MCF7 human breast carcinoma cells BT549 ductal breast carcinoma cells Human hTERT microvascular endothelial (HME1) cells Human hTERT immortalized retinal pigment epithelial (RPE1) cells Primary mouse aortic endothelial (MAE) cells	“Reticular adhesions”	(Lock et al., 2018)
PA-JEB/ $\beta 4$ and HaCaT human keratinocytes	Flat clathrin lattices/plaques	(Zuidema et al., 2018)
HeLa human cervical carcinoma cells* HepG2 human liver carcinoma* Caco-2 human colorectal adenocarcinoma cells* <i>* When cultured on glass or on collagen-coated polyacrylamide 31 kPa gels</i>	“Clathrin-coated plaques”	(Baschieri et al., 2018)
HeLa human cervical carcinoma cells	Flat clathrin lattices/plaques	(Leyton-Puig et al., 2017)
Primary mouse myotubes	Flat clathrin lattices/plaques	(Vassilopoulos et al., 2014)
Primary rat myotubes	“Clathrin-coated membrane domains”	(De Deyne et al., 1998)
M21 human melanoma cells H2981 and UCLA-P3 lung carcinoma cells	“Punctate distribution over the ventral cell surface outside FAs”	(Wayner et al., 1991)

- BASCHIERI, F., DAYOT, S., ELKHATIB, N., LY, N., CAPMANY, A., SCHAUER, K., BETZ, T., VIGNJEVIC, D. M., POINCLOUX, R. & MONTAGNAC, G. 2018. Frustrated endocytosis controls contractility-independent mechanotransduction at clathrin-coated structures. *Nat Commun*, 9, 3825.
- DE DEYNE, P. G., O'NEILL, A., RESNECK, W. G., DMYTRENKO, G. M., PUMPLIN, D. W. & BLOCH, R. J. 1998. The vitronectin receptor associates with clathrin-coated membrane domains via the cytoplasmic domain of its beta5 subunit. *J Cell Sci*, 111 (Pt 18), 2729-40.
- LEYTON-PUIG, D., ISOGAI, T., ARGENZIO, E., VAN DEN BROEK, B., KLARENBECK, J., JANSSEN, H., JALINK, K. & INNOCENTI, M. 2017. Flat clathrin lattices are dynamic actin-controlled hubs for clathrin-mediated endocytosis and signalling of specific receptors. *Nat Commun*, 8, 16068.
- LOCK, J. G., JONES, M. C., ASKARI, J. A., GONG, X., ODDONE, A., OLOFSSON, H., GORANSSON, S., LAKADAMYALI, M., HUMPHRIES, M. J. & STROMBLAD, S. 2018. Reticular adhesions are a distinct class of cell-matrix adhesions that mediate attachment during mitosis. *Nat Cell Biol*, 20, 1290-1302.
- VASSILOPOULOS, S., GENTIL, C., LAINE, J., BUCLEZ, P. O., FRANCK, A., FERRY, A., PRECIGOUT, G., ROTH, R., HEUSER, J. E., BRODSKY, F. M., GARCIA, L., BONNE, G., VOIT, T., PIETRI-ROUXEL, F. & BITOUN, M. 2014. Actin scaffolding by clathrin heavy chain is required for skeletal muscle sarcomere organization. *J Cell Biol*, 205, 377-93.
- WAYNER, E. A., ORLANDO, R. A. & CHERESH, D. A. 1991. Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. *J Cell Biol*, 113, 919-29.
- ZUIDEMA, A., WANG, W., KREFT, M., TE MOLDER, L., HOEKMAN, L., BLEIJERVELD, O. B., NAHIDIAZAR, L., JANSSEN, H. & SONNENBERG, A. 2018. Mechanisms of integrin alphaVbeta5 clustering in flat clathrin lattices. *J Cell Sci*, 131.

Table S2. Itg. $\beta 6$ vs Itg. $\beta 5_{IP_PA-JEB/\beta 4}$

					Two color points Chart 1	
Gene(s)	-LOG(P-value)	LFQ Abundance ratio (Itg. $\beta 6$ /Itg. $\beta 5$) (2Log)	Significant or Not Significant FDR = 0.05 and S0 = 0.1	Significant or Not Significant_FDR = 0.05 and S0 = 0.1	Significant	Not significant
IGLV3-9	3,046	3,318	+	Significant	3,318	#N/A
ARHGAP10	4,541	3,607	+	Significant	3,607	#N/A
NOP56	3,240	3,635	+	Significant	3,635	#N/A
ANKRD28	2,092	-3,244	+	Significant	-3,244	#N/A
P4HA2	4,235	3,646	+	Significant	3,646	#N/A
KLK10	1,572	-1,717	+	Significant	-1,717	#N/A
HNRNPR	1,776	1,696	+	Significant	1,696	#N/A
HTRA2	3,736	-4,106	+	Significant	-4,106	#N/A
BUB3	2,754	1,813	+	Significant	1,813	#N/A
MYO1B	4,054	3,411	+	Significant	3,411	#N/A
PRMT3	1,566	-1,977	+	Significant	-1,977	#N/A
C;HIST1H2BD;HIST1H2	4,601	4,542	+	Significant	4,542	#N/A
DKC1	1,495	1,724	+	Significant	1,724	#N/A
H2AFY	3,061	2,289	+	Significant	2,289	#N/A
ECI2	2,425	2,079	+	Significant	2,079	#N/A
UBR5	2,962	-2,597	+	Significant	-2,597	#N/A
NDUFB4	2,331	2,092	+	Significant	2,092	#N/A
ASMTL	1,788	2,473	+	Significant	2,473	#N/A
STAU1	2,392	-3,848	+	Significant	-3,848	#N/A
AIFM1	3,776	2,890	+	Significant	2,890	#N/A
PLG	3,507	3,019	+	Significant	3,019	#N/A
ASS1	2,614	2,433	+	Significant	2,433	#N/A
C5	1,979	-1,223	+	Significant	-1,223	#N/A
LMNA	1,995	1,656	+	Significant	1,656	#N/A
TFRC	3,860	1,440	+	Significant	1,440	#N/A
RPLP0;RPLP0P6	2,117	-0,830	+	Significant	-0,830	#N/A
KRT18	2,723	0,958	+	Significant	0,958	#N/A
IGKV4-1	3,093	1,443	+	Significant	1,443	#N/A
ITGAV	4,376	-1,840	+	Significant	-1,840	#N/A
PCL1;HNRNPCL3;HNRN	1,966	2,276	+	Significant	2,276	#N/A
RHOC;RHOA	3,723	2,276	+	Significant	2,276	#N/A
HSP90AB1	2,916	-0,890	+	Significant	-0,890	#N/A
PDHA1	1,438	-2,069	+	Significant	-2,069	#N/A
LGALS1	4,904	3,580	+	Significant	3,580	#N/A
DLD	1,692	-1,450	+	Significant	-1,450	#N/A
H2AFV;H2AFZ	1,461	2,230	+	Significant	2,230	#N/A
FJ;HIST1H2AH;HIST1H2	2,694	1,792	+	Significant	1,792	#N/A
PABPC1	3,001	0,438	+	Significant	0,438	#N/A
HARS	2,417	1,934	+	Significant	1,934	#N/A
CKMT1A	2,446	-1,097	+	Significant	-1,097	#N/A
P4HA1	2,344	-2,646	+	Significant	-2,646	#N/A

HNRNPL	1,741	1,978	+	Significant	1,978	#N/A
EZR	1,803	-0,968	+	Significant	-0,968	#N/A
HIST1H1B	1,369	2,592	+	Significant	2,592	#N/A
HIST1H1C;HIST1H1E;HIST1H1F	3,791	3,614	+	Significant	3,614	#N/A
PRKACA;PRKACB	2,163	-2,032	+	Significant	-2,032	#N/A
PTPN1	2,271	2,104	+	Significant	2,104	#N/A
ITGB5	3,797	-9,138	+	Significant	-9,138	#N/A
RPL7	2,075	-0,537	+	Significant	-0,537	#N/A
ITGB6	4,613	7,066	+	Significant	7,066	#N/A
ITIH2	3,321	-4,168	+	Significant	-4,168	#N/A
LMNB1	1,502	2,049	+	Significant	2,049	#N/A
SDHB	4,055	-3,434	+	Significant	-3,434	#N/A
TGM2	1,317	-2,680	+	Significant	-2,680	#N/A
FBL	2,017	3,016	+	Significant	3,016	#N/A
HNRNPA2B1	1,781	1,862	+	Significant	1,862	#N/A
SFPQ	1,672	1,161	+	Significant	1,161	#N/A
CFL1	2,713	2,693	+	Significant	2,693	#N/A
DGKA	1,816	-1,688	+	Significant	-1,688	#N/A
AZGP1	3,060	-0,609	+	Significant	-0,609	#N/A
DDX6	2,691	-1,391	+	Significant	-1,391	#N/A
RPL13	2,011	-0,740	+	Significant	-0,740	#N/A
SDHA	3,755	-6,512	+	Significant	-6,512	#N/A
RRM2	4,351	-5,297	+	Significant	-5,297	#N/A
HNRNPH3	1,701	1,231	+	Significant	1,231	#N/A
HNRNPH1	3,266	4,403	+	Significant	4,403	#N/A
YWHAB	3,485	-1,871	+	Significant	-1,871	#N/A
PYCR1	3,905	-2,810	+	Significant	-2,810	#N/A
KIF5B	3,016	-2,852	+	Significant	-2,852	#N/A
MYH10	3,368	4,055	+	Significant	4,055	#N/A
ADD1	2,321	-2,061	+	Significant	-2,061	#N/A
DLST	3,790	-1,732	+	Significant	-1,732	#N/A
ATP6V1A	1,321	5,315	+	Significant	5,315	#N/A
EIF4A3	1,693	1,868	+	Significant	1,868	#N/A
RFC3	2,561	-1,602	+	Significant	-1,602	#N/A
TMPO	1,645	1,498	+	Significant	1,498	#N/A
RPS27	1,932	0,793	+	Significant	0,793	#N/A
MATR3	1,718	3,197	+	Significant	3,197	#N/A
CSNK1A1;CSNK1A1L	2,150	-0,964	+	Significant	-0,964	#N/A
CSNK1D	1,385	-3,044	+	Significant	-3,044	#N/A
NUMB	2,408	2,110	+	Significant	2,110	#N/A
HSD17B4	2,051	0,941	+	Significant	0,941	#N/A
HMGA2	3,275	1,428	+	Significant	1,428	#N/A
ACLY	4,584	-6,383	+	Significant	-6,383	#N/A
VCP	3,146	-4,291	+	Significant	-4,291	#N/A
NHP2L1	1,938	2,498	+	Significant	2,498	#N/A
HNRNPK	1,935	1,262	+	Significant	1,262	#N/A
YWHAG	4,423	-1,788	+	Significant	-1,788	#N/A
RPS8	2,212	-0,660	+	Significant	-0,660	#N/A
RPS15A	3,084	-0,355	+	Significant	-0,355	#N/A
YWHAE	5,886	-1,540	+	Significant	-1,540	#N/A

SNRPD3	2,590	1,957	+	Significant	1,957	#N/A
HIST1H4A	1,726	2,102	+	Significant	2,102	#N/A
RPL8	2,982	-0,930	+	Significant	-0,930	#N/A
YWHAZ	5,099	-1,661	+	Significant	-1,661	#N/A
GTF2I	2,948	-3,183	+	Significant	-3,183	#N/A
SLC25A11	2,523	0,509	+	Significant	0,509	#N/A
REL	2,530	1,645	+	Significant	1,645	#N/A
YWHAH	3,560	-2,246	+	Significant	-2,246	#N/A
CSTF1	2,848	2,495	+	Significant	2,495	#N/A
CALD1	1,551	-2,618	+	Significant	-2,618	#N/A
CKAP4	2,151	-0,809	+	Significant	-0,809	#N/A
KLC1	2,532	-3,055	+	Significant	-3,055	#N/A
GOLGA2	2,251	-2,818	+	Significant	-2,818	#N/A
ILF3	2,106	1,180	+	Significant	1,180	#N/A
CSTF3	2,970	1,971	+	Significant	1,971	#N/A
TRIM28	2,767	1,426	+	Significant	1,426	#N/A
G3BP1	3,934	2,077	+	Significant	2,077	#N/A
PKP1	1,681	1,144	+	Significant	1,144	#N/A
DDX39B;DDX39A	1,526	1,739	+	Significant	1,739	#N/A
CUX1	3,241	-3,089	+	Significant	-3,089	#N/A
CAPRIN1	4,080	4,006	+	Significant	4,006	#N/A
DSC3	2,179	2,226	+	Significant	2,226	#N/A
KPNB1	1,973	0,742	+	Significant	0,742	#N/A
NUMA1	2,245	2,056	+	Significant	2,056	#N/A
GAPVD1	2,583	-10,265	+	Significant	-10,265	#N/A
EBP	2,240	1,856	+	Significant	1,856	#N/A
PLCB4	3,696	-2,618	+	Significant	-2,618	#N/A
PLEC	2,111	0,872	+	Significant	0,872	#N/A
PCBP1	4,077	2,000	+	Significant	2,000	#N/A
SF3B3	2,386	2,005	+	Significant	2,005	#N/A
MAPRE1	2,268	-2,875	+	Significant	-2,875	#N/A
DPYSL2	1,431	1,757	+	Significant	1,757	#N/A
SRSF7	1,485	1,756	+	Significant	1,756	#N/A
UPP1	1,482	3,322	+	Significant	3,322	#N/A
UGP2	2,568	-1,294	+	Significant	-1,294	#N/A
IMMT	1,962	0,824	+	Significant	0,824	#N/A
SMU1	1,879	2,483	+	Significant	2,483	#N/A
TMEM201	1,770	0,806	+	Significant	0,806	#N/A
FAM160B1	2,287	-3,294	+	Significant	-3,294	#N/A
CDC42BPG	3,630	-3,465	+	Significant	-3,465	#N/A
PTRF	2,025	0,649	+	Significant	0,649	#N/A
MARK2	4,950	-8,079	+	Significant	-8,079	#N/A
PM20D2	2,761	2,858	+	Significant	2,858	#N/A
KIAA0319L	3,313	3,185	+	Significant	3,185	#N/A
LSM14A	3,584	-3,960	+	Significant	-3,960	#N/A
MCU	2,069	0,579	+	Significant	0,579	#N/A
NPLOC4	3,408	-4,260	+	Significant	-4,260	#N/A
GEMIN5	3,102	2,212	+	Significant	2,212	#N/A
TTN	4,298	-2,957	+	Significant	-2,957	#N/A
DDX1	3,071	0,786	+	Significant	0,786	#N/A

ARHGEF1	3,709	-4,986	+	Significant	-4,986	#N/A
ARHGEF2	3,429	-4,971	+	Significant	-4,971	#N/A
HOOK2	2,979	-3,713	+	Significant	-3,713	#N/A
EDC3	3,578	3,415	+	Significant	3,415	#N/A
GRAMD3	2,869	2,056	+	Significant	2,056	#N/A
DOCK7	3,216	0,893	+	Significant	0,893	#N/A
CLCC1	1,703	1,127	+	Significant	1,127	#N/A
HNRNPAB	1,388	1,791	+	Significant	1,791	#N/A
C9orf156	3,619	-3,401	+	Significant	-3,401	#N/A
PRKD2	1,978	1,882	+	Significant	1,882	#N/A
VPS33B	2,982	-2,284	+	Significant	-2,284	#N/A
C2orf44	3,465	-5,314	+	Significant	-5,314	#N/A
RPRD1B	2,819	2,038	+	Significant	2,038	#N/A
DDX21	1,903	2,703	+	Significant	2,703	#N/A
ABHD10	2,664	-1,901	+	Significant	-1,901	#N/A
TECR	2,270	0,548	+	Significant	0,548	#N/A
LIMA1	3,399	4,530	+	Significant	4,530	#N/A
PSME2	2,114	-2,077	+	Significant	-2,077	#N/A
CORO1C	2,268	1,837	+	Significant	1,837	#N/A
G3BP2	2,465	1,851	+	Significant	1,851	#N/A
NUDC	5,287	-9,348	+	Significant	-9,348	#N/A
NOP58	2,673	2,825	+	Significant	2,825	#N/A
SNX24	3,260	-3,295	+	Significant	-3,295	#N/A
MTCL1	6,898	-8,439	+	Significant	-8,439	#N/A
MYO5A	2,622	4,691	+	Significant	4,691	#N/A
SAMM50	3,107	2,143	+	Significant	2,143	#N/A
ARFGEF1	4,747	2,728	+	Significant	2,728	#N/A

Table S3. Itg. β 6 vs Itg. β 5_IP_HaCat

Two color points Chart 1:

Gene(s)	-LOG(P-value)	LFQ Abundance ratio (ITGB6/ITGB5) (2Log)	Significant or Not Significant FDR = 0.05 and S0 = 0.1	Significant or Not Significant_FD R = 0.05 and S0 = 0.1	Significant	Not significant
IGLV3-9	3,647	4,764	+	Significant	4,764	#N/A
CUX2	4,866	-6,418	+	Significant	-6,418	#N/A
P4HA2	2,776	3,298	+	Significant	3,298	#N/A
HTRA2	2,725	-3,825	+	Significant	-3,825	#N/A
NUDT21	1,612	-1,364	+	Significant	-1,364	#N/A
PPL	2,140	1,788	+	Significant	1,788	#N/A
SYNCRIP	2,151	0,549	+	Significant	0,549	#N/A
PRMT3	3,245	-2,878	+	Significant	-2,878	#N/A
SF3B1	2,063	1,375	+	Significant	1,375	#N/A
ASMTL	2,587	1,611	+	Significant	1,611	#N/A
STAU1	4,005	-5,635	+	Significant	-5,635	#N/A
AIFM1	3,486	3,759	+	Significant	3,759	#N/A
ASS1	3,424	4,328	+	Significant	4,328	#N/A
A2M	3,241	0,844	+	Significant	0,844	#N/A
C3	2,481	0,963	+	Significant	0,963	#N/A
FN1	3,516	-0,897	+	Significant	-0,897	#N/A
TFRC	4,251	1,636	+	Significant	1,636	#N/A
TF	3,080	1,450	+	Significant	1,450	#N/A
RPLP0;RPLP0P6	3,072	-0,905	+	Significant	-0,905	#N/A
ITGAV	4,656	-2,505	+	Significant	-2,505	#N/A
P4HB	3,093	1,251	+	Significant	1,251	#N/A
PABPC1	2,982	1,116	+	Significant	1,116	#N/A
CKMT1A	2,711	-4,101	+	Significant	-4,101	#N/A
PTPN1	3,407	2,621	+	Significant	2,621	#N/A
ITGB5	3,398	-9,331	+	Significant	-9,331	#N/A
RPL7	2,049	-0,729	+	Significant	-0,729	#N/A
ITGB6	5,837	6,534	+	Significant	6,534	#N/A
NCL	3,249	-0,718	+	Significant	-0,718	#N/A
TRIM21	2,786	3,347	+	Significant	3,347	#N/A
ITIH2	4,624	-3,488	+	Significant	-3,488	#N/A
SDHB	2,445	-3,240	+	Significant	-3,240	#N/A
TGM2	1,627	-3,883	+	Significant	-3,883	#N/A
TUBG1;TUBG2	2,148	-1,217	+	Significant	-1,217	#N/A
DNAJB1	2,811	0,978	+	Significant	0,978	#N/A
ATP5A1	2,883	0,715	+	Significant	0,715	#N/A
DDX6	4,457	-7,882	+	Significant	-7,882	#N/A
PTBP1	3,813	3,390	+	Significant	3,390	#N/A
CALR	2,858	-2,595	+	Significant	-2,595	#N/A
CANX	3,278	-2,459	+	Significant	-2,459	#N/A
NOS1	3,207	2,764	+	Significant	2,764	#N/A

RPL12	1,894	-0,889	+	Significant	-0,889	#N/A
ADSL	2,261	-2,230	+	Significant	-2,230	#N/A
SDHA	2,964	-3,699	+	Significant	-3,699	#N/A
RRM2	4,475	-5,004	+	Significant	-5,004	#N/A
YWHAB	2,540	-0,679	+	Significant	-0,679	#N/A
RPL9	2,829	-0,527	+	Significant	-0,527	#N/A
KIF5B	2,756	-2,403	+	Significant	-2,403	#N/A
ADD1	1,545	-1,502	+	Significant	-1,502	#N/A
IGFALS	2,157	-1,410	+	Significant	-1,410	#N/A
ATP6V1A	5,813	7,405	+	Significant	7,405	#N/A
RPL3	2,487	-0,498	+	Significant	-0,498	#N/A
DDOST	2,707	-2,176	+	Significant	-2,176	#N/A
RPL5	2,564	-0,650	+	Significant	-0,650	#N/A
RPL28	2,722	-0,841	+	Significant	-0,841	#N/A
SERPINH1	2,548	1,259	+	Significant	1,259	#N/A
RPL14	3,829	-4,129	+	Significant	-4,129	#N/A
FXR1	3,339	-1,268	+	Significant	-1,268	#N/A
ACLY	3,691	-4,483	+	Significant	-4,483	#N/A
RPL15	4,164	-0,918	+	Significant	-0,918	#N/A
RPL27	2,066	-0,778	+	Significant	-0,778	#N/A
YWHAG	3,938	-1,235	+	Significant	-1,235	#N/A
YWHAE	3,451	-1,530	+	Significant	-1,530	#N/A
RPL30	2,562	-0,968	+	Significant	-0,968	#N/A
RPL10A	1,997	-0,693	+	Significant	-0,693	#N/A
YWHAZ	2,633	-1,092	+	Significant	-1,092	#N/A
TUBA4A	2,270	0,537	+	Significant	0,537	#N/A
GTF2I	2,530	-4,431	+	Significant	-4,431	#N/A
RPL19	2,078	-0,793	+	Significant	-0,793	#N/A
SORD	4,183	-2,960	+	Significant	-2,960	#N/A
KIF23	2,064	1,862	+	Significant	1,862	#N/A
REL	2,462	1,902	+	Significant	1,902	#N/A
YWHAH	2,915	-1,571	+	Significant	-1,571	#N/A
RPL18	1,517	-2,499	+	Significant	-2,499	#N/A
KLC1	2,592	-3,367	+	Significant	-3,367	#N/A
GOLGA2	3,272	-2,922	+	Significant	-2,922	#N/A
ILF2	1,405	-2,024	+	Significant	-2,024	#N/A
TRIM28	2,652	1,496	+	Significant	1,496	#N/A
G3BP1	4,639	3,225	+	Significant	3,225	#N/A
SQSTM1	2,384	1,439	+	Significant	1,439	#N/A
CUX1	3,793	-2,870	+	Significant	-2,870	#N/A
TRIM29	2,865	0,394	+	Significant	0,394	#N/A
DYNC1H1	4,855	-2,966	+	Significant	-2,966	#N/A
MAP7	3,541	-0,449	+	Significant	-0,449	#N/A
CAPRIN1	2,512	3,999	+	Significant	3,999	#N/A
GAPVD1	2,591	-7,647	+	Significant	-7,647	#N/A
PON3	4,823	-4,598	+	Significant	-4,598	#N/A
MAPRE1	3,665	-3,458	+	Significant	-3,458	#N/A
UPP1	1,584	2,921	+	Significant	2,921	#N/A
PTRF	3,381	0,715	+	Significant	0,715	#N/A
MTHFD1L	2,064	-0,631	+	Significant	-0,631	#N/A

MARK2	3,861	-8,390	+	Significant	-8,390	#N/A
LSM14A	2,896	-4,340	+	Significant	-4,340	#N/A
NPLOC4	2,320	-2,413	+	Significant	-2,413	#N/A
GEMIN5	1,548	1,578	+	Significant	1,578	#N/A
PPP1R13L	2,943	0,491	+	Significant	0,491	#N/A
TTN	4,414	-3,141	+	Significant	-3,141	#N/A
ARHGEF1	3,884	-5,010	+	Significant	-5,010	#N/A
UFD1L	2,658	-2,335	+	Significant	-2,335	#N/A
ARHGEF2	4,061	-5,655	+	Significant	-5,655	#N/A
HOOK2	3,353	-4,099	+	Significant	-4,099	#N/A
EDC3	5,349	4,711	+	Significant	4,711	#N/A
DOCK7	3,287	1,886	+	Significant	1,886	#N/A
C9orf156	2,575	-3,518	+	Significant	-3,518	#N/A
PRKD2	3,616	2,962	+	Significant	2,962	#N/A
VPS33B	2,304	-2,709	+	Significant	-2,709	#N/A
OSBPL3	2,268	0,608	+	Significant	0,608	#N/A
RABEP2	3,605	2,175	+	Significant	2,175	#N/A
C2orf44	2,433	-4,974	+	Significant	-4,974	#N/A
VIPAS39	2,249	-3,009	+	Significant	-3,009	#N/A
RPRD1B	2,213	2,055	+	Significant	2,055	#N/A
44448	2,102	1,946	+	Significant	1,946	#N/A
PSME2	4,357	-2,666	+	Significant	-2,666	#N/A
G3BP2	4,495	2,869	+	Significant	2,869	#N/A
NUDC	2,912	-9,358	+	Significant	-9,358	#N/A
SNX24	3,571	-3,336	+	Significant	-3,336	#N/A
MYO5A	2,559	3,808	+	Significant	3,808	#N/A
DNAJC15	2,506	-1,900	+	Significant	-1,900	#N/A
PEX16	1,949	-0,679	+	Significant	-0,679	#N/A
ARFGEF1	2,562	3,544	+	Significant	3,544	#N/A

Table S4. Primary antibody list

Antibody	Clone	Obtained from	Host	Application
Integrin β5	EM09902	Simon Goodman (Merck KGaA)	Rabbit mAb	IF/FACS: 1:200
Integrin β5 - cyto	5HK2	Homemade	Rabbit pAb	WB: 1:1000 IP: 1 μ l / sample
Integrin β1 - cyto	U19	Ulrike Mayer	Rabbit pAb	WB: 1:1000
Integrin β3	C17	Ellen van der Schoot	Mouse mAb	FACS: 1:100
Integrin β6 - cyto	5HK1	Homemade	Rabbit pAb	IP: 1 μ l / sample
Vinculin	VIIIF9	Marina Glukhova	Mouse mAb	IF: 1:5
Talin	8d4	Sigma	Mouse mAb	IF: 1:200 WB: 1:1000
ARH/LDLRAP1		AntibodyPlus (#A7093)	Rabbit pAb	WB: 1:1000
Numb	S.925.4	Invitrogen (#MA5-14897)	Rabbit mAb	WB: 1:1000
Clathrin, Heavy chain	X22	Thermo Fisher (#MA1-065)	Mouse mAb	IF: 1:400
Dab2		Cell Signaling (#12906)	Rabbit mAb	WB: 1:500
Kindlin-1		Homemade (Ussar et al., 2006)	Rabbit pAb	WB: 1:5000
Kindlin-2	3A3	EMD Millipore (#MAB2617)	Mouse mAb	WB: 1:1000
KANK-2		Sigma (#HPA015643)	Rabbit pAb	WB: 1:2000
SNX17		ProteinTech (#10275-1-AP)	Rabbit pAb	WB: 1:1000
Akt-phospho S473		Cell Signaling Technology (#9271)	Rabbit pAb	WB: 1:1000
Akt		Cell Signaling Technology (#9272)	Rabbit pAb	WB: 1:1000
Erk1/2-diphospho		Sigma (#M8159)	Mouse mAb	WB: 1:1000
Erk1/2		Cell Signaling (#9102)	Rabbit pAb	WB: 1:1000
FAK-phospho Y397		Invitrogen (#44624G)	Rabbit pAb	WB: 1:1000
FAK	77	BD Bioscience #610087	Mouse mAb	WB: 1:1000
GEF-H1-phospho S886	E1L6D	Cell Signaling Technology (#14143)	Rabbit mAb	WB: 1:1000
GEF-H1		Abcam (#ab155785)	Rabbit pAb	WB: 1:1000
MARK2		Proteintech (#15492-1-AP)	Rabbit pAb	WB: 1:1000
MARK2		Cell Signaling Technology (#9118)	Rabbit pAb	WB: 1:1000
MLC-phospho S19		Cell Signaling Technology (#3671)	Rabbit pAb	WB: 1:500
P115 RhoGEF	C-19	Santa Cruz	Goat pAb	WB: 1:1000
GAPDH	6C5	EMD Millipore (#CB1001)	Mouse mAb	WB: 1:5000